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Highlights: 
• This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for 
managing advanced breast cancer patients 
• It provides updates on the management of patients with all breast cancer subtypes, LABC, 
follow-up, palliative and supportive care 
• Updated diagnostic and treatment algorithms are also provided 
• All recommendations were compiled by a multidisciplinary group of international experts 
• Recommendations are based on available clinical evidence and the collective expert 






For the purpose of ABC guidelines, advanced breast cancer (ABC) comprises both inoperable 
locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).1,2 
Advanced/metastatic breast cancer remains a virtually incurable disease, with a median 
overall survival (OS) of about 3 years and a 5-year survival rate of around 25%,3,4 even in 
countries without major accessibility problems. Survival is strongly related to breast cancer 
subtype, with the major advances seen in human epidermal growth factor receptor 2 (HER2)-
positive ABC.5-9 ABC is a treatable disease with several available therapies and many others 
in development. However, their impact on survival and quality of life (QoL) of ABC patients 
has been slow3 and different for de novo versus recurrent ABC, with the latter becoming 
much harder to treat in recent years.10 Outcomes are also strongly related to access to the 
best available care, which includes not only the most efficacious medicines, but also 
multidisciplinary, specialised care, implementation of guidelines, high quality pathology, 
imaging and radiotherapy (RT). Lack of any of these crucial pillars of modern oncological care 
inevitably results in substantially worse outcomes, as exemplified in the New Zealand report “I 
am still here”.11 While mortality rates have decreased in the majority of developed countries, 
most deaths are currently seen in less developed societies, and access issues explain the 
majority of these inequalities.12 
The application of the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS)13 to 
the field of ABC14 shows that the quality of clinical research has improved over the last 
decade and that better therapies have been developed, providing hope that a substantial 
improvement in the median OS of ABC patients might soon be seen. However, some clinically 
relevant questions are still unanswered and may be difficult to address through traditional 
clinical trials, such as the best sequence of therapies for each individual patient. The 
application of computer analytics to big data and real-word data is one of the potential ways 
forward. In depth discussion must take place regarding the impact of this ‘new’ level of 
evidence (LoE) into current treatment guidelines and their integration with clinical trial data. 
The 5th International Consensus Conference for Advanced Breast Cancer (ABC 5) 
took place in Lisbon, Portugal, on 14th–16th November 2019, bringing together 1500 
participants from 94 countries worldwide, including health professionals, patient advocates 
and journalists. Since its first edition in 2011, the main goal of the ABC conference has been 
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the development of high-quality international consensus guidelines for the management of 
ABC. These guidelines are based on available evidence and on expert opinion when 
evidence is lacking. They represent the best management options for ABC patients globally, 
assuming accessibility to all available therapies. Adaptation of these guidelines is often 
needed in settings where access to care is suboptimal. 
The ABC 5 guidelines are jointly developed by ESO and ESMO, and have been 
endorsed by several international oncology organisations, such as the European Society of 
Breast Cancer Specialists (EUSOMA), European Society for Radiotherapy and Oncology 
(ESTRO), European Society of Gynaecological Oncology (ESGO), Union for International 
Cancer Control (UICC), Senologic International Society (SIS) / International School of 
Senology (ISS), Federación Latino-Americana de Mastologia (FLAM), European Oncology 
Nursing Society (EONS), European Society of Surgical Oncology (ESSO), 
Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (AGO) and the International Society of 
Geriatric Oncology (SIOG), and have official representation from the American Society of 
Clinical Oncology (ASCO). The ABC 5 conference was also organised under the auspices of 
the Organisation of European Cancer Institutes (OECI) and with the support of the Breast 
Cancer Research Foundation (BCRF), Susan G. Komen and the ABC Global Alliance. 
This manuscript summarises the guidelines developed at ABC 5, each of which are 
accompanied by the LoE, grade of recommendation (GoR), percentage of consensus 
reached at the conference and supporting references. In addition, the ESMO-MCBS version 
1.113 (v1.1) was used to calculate scores for new therapies/indications approved by the 
European Medicines Agency (EMA) since the last ABC guidelines, as well as a few new 
therapies that have been scored but are still under EMA evaluation 
(https://www.esmo.org/Guidelines/ESMO-MCBS). A table with these scores is included (see 
Supplementary Table S1, available at Annals of Oncology online). 
 
METHODOLOGY 
Before the ABC 5 conference, preliminary recommendation statements on the management 
of ABC were prepared based on available published data and following the ESMO guidelines 
methodology (see http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology). These 
recommendations were circulated to all 44 panel members by email for comments and 
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corrections on content and wording. A final set of recommendations was presented, 
discussed and voted upon during the consensus session of ABC 5. All panel members were 
instructed to vote on all questions, and any members with a potential conflict of interest or 
who did not feel comfortable answering the question (e.g. due to lack of expertise in a 
particular field) were instructed to vote ‘abstain’. Additional changes in the wording of 
statements were made during the session. As some important studies were presented a few 
weeks later at the 2019 San Antonio Breast Cancer Symposium, particularly for new anti-
HER2 therapies, three additional statements were developed after the ABC 5 conference, 
circulated for revision and voted by all panel members. Statements related to the 
management of side effects and difficult symptoms, included under the supportive and 
palliative care section, were not voted on during the consensus session, but were discussed 
and unanimously agreed by email, and are therefore considered to have 100% consensus 
agreement. Previous ABC recommendations that did not require update or only minor 
changes were not re-voted but were reviewed by all panel members by email and remain 
valid. To provide a full overview of all ABC guidelines currently approved, this manuscript 
includes a list of all recommendations per subject, highlighting those that were discussed, 
voted and approved in ABC 5. However, this manuscript only describes the evidence for 
newly developed or updated guidelines. We refer the reader to the manuscripts of previous 
ABC guidelines for the detailed explanation of guidelines not updated/added during ABC 5. 
Supplementary Table S2, available at Annals of Oncology online, describes the LoE 
and GoR system used,15 as per ESMO guidelines methodology.  
Supplementary Figures, available at Annals of Oncology online, feature updated ABC 
diagnostic and treatment algorithms. 






Section I: ABC definitions 
Guideline statement LoE/GoR Consensus 
Visceral crisis is defined as severe organ dysfunction, as assessed by signs and 
symptoms, laboratory studies and rapid progression of disease. Visceral crisis is not the 
mere presence of visceral metastases but implies important organ compromise leading 
to a clinical indication for the most rapidly efficacious therapy. 
Examples: Liver visceral crisis: rapidly increasing bilirubin >1.5x ULN in the absence of 
Gilbert’s Syndrome or biliary tract obstruction. Lung visceral crisis: rapidly increasing 




Primary endocrine resistance is defined as relapse while on the first 2 years of 
adjuvant ET, or PD within first 6 months of first-line ET for ABC, while on ET. 
Secondary endocrine resistance is defined as relapse while on adjuvant ET but after 
the first 2 years, or relapse within 12 months of completing adjuvant ET, or PD ≥6 




Oligometastatic disease is defined as low volume metastatic disease with limited 
number and size of metastatic lesions (up to five and not necessarily in the same organ), 




Patients with multiple chronic conditions are defined as patients with additional 
comorbidities (e.g. cardiovascular, impaired renal or liver function, autoimmune disease) 
making it difficult to account for all of the possible extrapolations to develop specific 






Adequate OFS in the context of ABC:  
Adequate OFS for ABC premenopausal patients can be obtained through bilateral 
ovariectomy, continuous use of LHRH agonists or OFA through pelvic RT (the latter is 
not always effective and therefore is the least preferred option). 
If an LHRH agonist is used in this age group, it should usually be given on a q4w basis 
to optimise OFS. 
Efficacy of OFS must be initially confirmed analytically through serial evaluations of 
serum oestradiol, even in the presence of amenorrhoea, especially if an AI is 
administered. 
As all endocrine interventions for premenopausal patients with endocrine-responsive 
ABC require indefinite OFS, choosing one method over the other requires a balance of 
the patient’s wish for potentially preserving fertility, compliance with frequent injections 

















Maintenance therapy: in the context of ABC guidelines, maintenance therapy refers to 




Integrative medicine: complementary and integrative medicine (CIM) represents the 





In green, NEW/UPDATED ABC 5 statements.  
ABC, advanced breast cancer; AI, aromatase inhibitor; consensus, percentage of panel members in agreement with the 
statement; ChT, chemotherapy; ET, endocrine therapy; GoR, grade of recommendation; HER2, human epidermal growth factor 
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receptor 2; LHRH, luteinising hormone-releasing hormone; LoE, level of evidence; n/a, not applicable; OFA, ovarian function 





Given the aim of standardising definitions and homogenising the use of certain medical terms, 
ABC has provided several definitions throughout the years. At ABC 5, the definition of visceral 
crisis was revisited, with some examples added (i.e. liver and lung visceral crisis) to better 
clarify the definition and avoid any misunderstanding between the mere existence of visceral 
metastases and the presence of visceral crisis. This situation is estimated to occur in only 
around 10%–15% of first-line ABC cases and requires the use of the most rapidly efficacious 
therapy, which is not necessarily chemotherapy (ChT) in all situations. 
A more subjective and difficult to define situation is ‘impending visceral crisis’, where 
the criteria for visceral crisis are not yet met but, without rapidly efficacious measures, it is 
foreseen to happen. An example is a situation where more than 70% of the liver is occupied 
by metastases, the liver enzymes are substantially altered but bilirubin is still normal. In this 





Section II: general guidelines 
Guideline statement LoE/GoR Consensus 
The management of ABC is complex and, therefore, involvement of all appropriate specialties in a 
multidisciplinary team (including but not restricted to medical, radiation and surgical oncologists, 
imaging experts, pathologists, gynaecologists, psycho-oncologists, social workers, nurses and 
palliative care specialists) is crucial. 
Expert opinion/A 100% 
From the time of diagnosis of ABC, patients should be offered appropriate psychosocial care, 
supportive care and symptom-related interventions as a routine part of their care. The approach 
must be personalised to meet the needs of the individual patient. 
Expert opinion/A 100% 
Following a thorough assessment and confirmation of MBC, the potential treatment goals of care 
should be discussed. Patients should be told that MBC is incurable but treatable, and that some 
patients can live with MBC for extended periods of time (many years in some circumstances). 
This conversation should be conducted in the accessible language, respecting patient privacy and 
cultural differences, and whenever possible, written information should be provided. 
Expert opinion/A 97% 
All ABC patients should be offered comprehensive, culturally sensitive, up-to-date and easy-to-
understand information about their disease and its management. 
I/A 97% 
Patients (and their families, caregivers or support network, if the patient agrees) should be invited to 
participate in the decision-making process at all times. When possible, patients should be 
encouraged to be accompanied by persons who can support them and share treatment decisions 
(e.g. family members, caregivers, support network). 
Expert opinion/A 100% 
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Every ABC patient must have access to optimal cancer treatment and supportive care according to 
the highest standards of patient-centred care, as defined by: 
• Open communication between patients and their cancer care teams as a primary goal. 
• Educating patients about treatment options and supportive care, through development and 
dissemination of evidence-based information in a clear, culturally appropriate form. 
• Encouraging patients to be proactive in their care and to share decision making with their 
healthcare providers. 
• Empowering patients to develop the capability of improving their own QoL within their cancer 
experience. 
• Always taking into account patient preferences, values and needs as essential to optimal 
cancer care. 
• Patients should have easy access to well-designed clinical studies since these are crucial for 
further improvement in the management of ABC. 
Expert opinion/A 100% 
Every ABC patient should: 
• Have access to the most up-to-date treatments and innovative therapies at accessible breast 
units/centres. 
• Be treated in specialist breast units/centres/services (SBUs) by a specialised multidisciplinary 
team including specialised side effects management and a nurse experienced in the 
treatment of ABC. 












• A quality assurance programme covering the entire breast cancer pathway from screening 
and diagnosis to treatment, rehabilitation, follow-up and palliative care, including services and 
support for ABC patients and their caregivers, should be implemented by SBUs. 
Expert opinion/B 
General statements: QoL   
Strong consideration should be given to the use of validated PROMs for patients to record the 
symptoms of disease and side effects of treatment experienced as a regular part of clinical care. 
These PROMs should be simple and user-friendly to facilitate their use in clinical practice and 
thought needs to be given to the easiest collection platform e.g. tablets or smartphones. Systematic 
monitoring would facilitate communication between patients and their treatment teams by better 
characterising the toxicities of all anticancer therapies. This would permit early intervention of 
supportive care services enhancing QoL. 
I/C 87% 
Specific tools for evaluation of QoL in ABC patients should be developed. 
Until then, trials evaluating QoL in this setting should use standardised PROs (instead of focusing 
exclusively on CTCAEs) and incorporate specific site- and treatment-specific modules or subscales 
that exist both in the EORTC and FACT systems. 
Additionally, attention needs to be paid to collection methods, timing of assessments and handling of 
missing data. More sophisticated statistics should also be employed to ensure that clinicians have 





General statements: clinical trials   
After appropriate informed consent, inclusion of patients in well-designed, prospective, independent 
trials must be a priority whenever such trials are available and the patient is willing to participate. 
Expert opinion/A 100% 
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The ABC community strongly calls for clinical trials addressing important unanswered clinical 
questions in this setting, and not just for regulatory purposes. Clinical trials should continue to be 
performed, even after approval of a new treatment, to provide real-world data on its performance, 
efficacy and toxicity. 
Expert opinion/A 100% 
General statements: affordability/cost effectiveness   
The medical community is aware of the problems raised by the cost of ABC treatment. Balanced 
decisions should be made in all instances; patients’ well-being, length of life and preferences should 
always guide decisions. 
Expert opinion/A 100% 
We strongly recommend the use of objective scales, such as the ESMO-MCBS or the ASCO Value 
Framework, to evaluate the real magnitude of benefit provided by a new treatment and help 
prioritise funding, particularly in countries with limited resources. 
Expert opinion/A 88% 
The ABC community strongly supports the use of biosimilars both for treatment of breast cancer 
(i.e. trastuzumab) and for supportive care (i.e. growth factors). To be used, the biosimilar must be 
approved after passing the stringent development and validation processes required by the EMA or 
the FDA or other similarly strict authority. 
I/A 90% 
General statements: survivorship   
As survival is improving in many patients with ABC, consideration of survivorship issues should be 
part of the routine care of these patients. Health professionals should therefore be ready to change 
and adapt treatment strategies to disease status, treatment of adverse effects and QoL, patients’ 
priorities and life plans. Attention to chronic needs for home and family care, job and social 
requirements, should be incorporated in the treatment planning and periodically updated. 
Expert opinion/A 95% 
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ABC patients who desire to work or need to work for financial reasons should have the opportunity to 
do so, with needed and reasonable flexibility in their working schedules to accommodate continuous 
treatment and hospital visits. 
Expert opinion/A 100% 
ABC patients with stable disease being treated as a ‘chronic condition’ should have the option to 
undergo breast reconstruction if clinically appropriate.  
Expert opinion/B 82% 





Breast imaging should also be performed when there is a suspicion of locoregional progression. I/A 100% 
Fertility preservation: the impact of the anticancer therapies on fertility should be discussed with all 
women with ABC of childbearing age, and their partners, before the start of treatment. The 
discussion must also include appropriate information about the prognosis of the disease and the 
potential consequences of pregnancy (e.g. stopping ongoing treatment). 
Expert opinion/B 100% 
General statements: other   
Specialised oncology nurses (if possible specialised breast nurses) should be part of the 
multidisciplinary team managing ABC patients. In some countries, this role may be played by a 
physician assistant or another trained and specialised healthcare practitioner. 
Expert opinion/A 92% 
The use of telemedicine in oncology to help management of patients with ABC living in remote 
places is an important option to consider when geographic distances are a problem and provided 
that issues of connectivity are solved. 
Expert opinion/B 93% 
In green, NEW/UPDATED ABC 5 statements. 
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ABC, advanced breast cancer; ASCO, American Society of Clinical Oncology; consensus, percentage of panel members in 
agreement with the statement; CTCAE, Common Terminology Criteria for Adverse Events; EMA, European Medicines Agency; 
EORTC, European Organisation for Research and Treatment of Cancer; ESMO-MCBS, European Society for Medical 
Oncology Magnitude of Clinical Benefit Scale; FACT, Functional Assessment of Cancer Therapy; FDA, Food and Drug 
Administration; GoR, grade of recommendation; LoE, level of evidence; MBC, metastatic breast cancer; PRO, patient-reported 





Fortunately, these last few years have seen the development and approval of several new 
therapies for ABC, some with an impact on OS. Consequently, some ABC patients can live 
many years with their disease under control or in complete remission. Since the usual 
methods for systemic imaging of metastatic disease do not provide good imaging of the 
breast, the panel believes that breast imaging is an option to consider in the surveillance 
follow-up of these patients. Additionally, and importantly, if at any time locoregional relapse or 
progression is suspected, breast imaging must be carried out. 
At ABC 5, several discussions took place regarding how best to provide information 
regarding prognosis and length of life to ABC patients. Conversations about prognosis, 
priorities and end-of-life care are vitally important for those affected by advanced cancer and 
should be part of routine care.16 Information about prognosis and likely survival time with and 
without different anticancer treatments is important to enable fully informed and educated 
decision-making by patients. It also helps patients to plan for the future, arrange finances and 
work, maximise time with loved ones, plan special events and prepare for death. 
Misunderstandings about prognosis are common17-19 and are associated with increased 
exposure to futile treatments.20-23 Most patients want considerably more information than 
many healthcare professionals expect, but the type and amount of information sought should 
be clarified.24 There are some significant cultural variations, in particular the involvement of 
the family in filtering information, which can make disclosure about prognosis and survival 
especially challenging.25 Although some physicians may avoid discussing prognosis for fear 
of upsetting the patient or destroying hope, there is no evidence that increased information 
about prognosis with sensitive communication is harmful to patients, or that it increases 
anxiety or distress.26-31 For patients wanting quantitative information on life expectancy, 
providing ranges for worst-case, typical and best-case scenarios is more helpful and conveys 
more hope than providing a single point estimate of median survival.32 Ranges for survival 
scenarios are also more accurate than a single point estimate of expected survival.17,33,34 
Oncologists should offer prognostic information to all patients with ABC, allowing patients to 
determine the type and extent of information required. The patient’s needs for prognostic 
information are likely to fluctuate over time, and as their disease progresses, so it is important 
for oncologists to repeatedly determine the information required throughout the illness from 
diagnosis to death. Oncologists also need guidance and communication skills training on how 
to handle these difficult discussions, as there is evidence that some oncologists are overly 
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optimistic about survival benefits from anticancer treatments while others are unduly nihilistic 




Section III: assessment and treatment general guidelines 
Guideline statement LoE/GoR Consensus 
Image and disease assessment guidelines   
Minimal staging work-up for ABC includes a history and physical examination, haematology and 
biochemistry tests and imaging of the chest, abdomen and bones. 
II/A 67% 
Brain imaging should not be routinely performed in asymptomatic patients. This approach is 
applicable to all patients with ABC, including those with HER2-positive and/or triple-negative ABC. 
II/D 94% 
The clinical value of tumour markers is not well established for diagnosis or follow-up after adjuvant 
therapy, but their use (if elevated) as an aid to evaluate response to treatment, particularly in 
patients with non-measurable metastatic disease, is reasonable. An increase in tumour markers 
alone should not be used to initiate a change in treatment. 
II/C 89% 
Evaluation of response to therapy should generally occur every 2–4 months for ET or after 2–4 
cycles for ChT, depending on the dynamics of the disease, the location and extent of metastatic 
involvement and type of treatment. Imaging of a target lesion may be sufficient in many patients. In 
certain patients, such as those with indolent disease, less frequent monitoring is acceptable. 
Additional testing should be performed in a timely manner, irrespective of the planned intervals, if PD 
is suspected or new symptoms appear. A thorough history and physical examination must always be 
performed. 
Expert opinion/B 81% 
Biopsy guidelines   
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A biopsy (preferably providing histology) of a metastatic lesion should be performed, if easily 
accessible, to confirm diagnosis, particularly when metastasis is diagnosed for the first time. 
I/B 98% 
Biological markers (especially HR and HER2) should be reassessed at least once in the metastatic 
setting, if clinically feasible. Depending on the metastatic site (e.g. bone tissue), technical 
considerations need to be discussed with the pathologist. 
I/B 98% 
If the results of tumour biology in the metastatic lesion differ from the primary tumour, it is currently 
unknown which result should be used for treatment decision making. Since a clinical trial addressing 
this issue is difficult to undertake, we recommend considering the use of targeted therapy (ET and/or 
anti-HER2 therapy) when receptors are positive in at least one biopsy, regardless of timing. 
Expert opinion/B 87% 
Locoregional treatment general guidelines   
To date, the removal of the primary tumour in patients with de novo stage IV breast cancer has 
not been associated with prolongation of survival, with the possible exception of the subset of 
patients with bone-only disease. However, it can be considered in selected patients with controlled 
systemic disease, particularly to improve QoL, always taking into account the patient’s preferences. 
Of note, some studies suggest that surgery is only valuable if performed with the same attention to 
detail (e.g. complete removal of the disease) as in patients with early-stage disease. 
Additional prospective clinical trials evaluating the value of this approach, the best candidates and 













A small but very important subset of patients with ABC, for example those with oligometastatic 
disease or low-volume metastatic disease that is highly sensitive to systemic therapy, can 
achieve complete remission and a long survival. A multimodal approach, including locoregional 
Expert opinion/B 91% 
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treatments with curative intent, should be considered for these selected patients. A prospective 
clinical trial addressing this specific situation is needed. 
Systemic treatment general guidelines   
Treatment choice should take at least these factors into account:  
HR and HER2 status and germline BRCA status, PIK3CA in HR-positive and PD-L1 in TNBC, if 
targeted therapies are accessible. Previous therapies and their toxicities, DFI, tumour burden 
(defined as number and site of metastases), biological age, PS, comorbidities (including organ 
dysfunctions), menopausal status (for ET), the need for rapid disease/symptom control, socio-
economic and psychological factors, available therapies in the patient’s country and patient’s 
preference. 
Expert opinion/A 95% 
The age of the patient should not be the sole reason to withhold effective therapy (in elderly patients) 
nor to overtreat (in young patients). Age alone should not determine the intensity of treatment. 
I/E 100% 
ChT general guidelines   
Both combination and sequential, single-agent ChT are reasonable options. Based on the available 
data, we recommend sequential monotherapy as the preferred choice for ABC. Combination ChT 
should be reserved for patients with rapid clinical progression, life-threatening visceral metastases or 
the need for rapid symptom and/or disease control. 
I/A 96% 
In the absence of medical contraindications or patient concerns, anthracycline- or taxane-based 
regimens, preferably as single agents, would usually be considered as first-line ChT for HER2-




and for whom ChT is appropriate. Other options are, however, available and effective, such as 
capecitabine and vinorelbine, particularly if avoiding alopecia is a priority for the patient. 
In patients with taxane-naive and anthracycline-resistant ABC or with anthracycline maximum 
cumulative dose or toxicity (i.e. cardiac) who are being considered for further ChT, taxane-based 
therapy, preferably as single agent, would usually be considered as the treatment of choice. Other 
options are, however, available and effective, such as capecitabine and vinorelbine, particularly if 
avoiding alopecia is a priority for the patient. 
I/A 59% 
In patients pre-treated (in the adjuvant and/or metastatic setting) with an anthracycline and a taxane, 
single-agent capecitabine, vinorelbine or eribulin are the preferred choices. Additional choices 
include gemcitabine, platinum agents, a different taxane and liposomal anthracyclines. The decision 
should be individualised and take into account different toxicity profiles, previous exposure, patient 
preferences and country availability. 
I/A 77% 
If given in the adjuvant setting, a taxane can be re-used as first-line therapy, particularly if there has 
been at least one year of DFI. 
I/B 92% 
If given in the adjuvant setting, provided that maximum cumulative dose has not been achieved and 
there are no cardiac contraindications, anthracyclines can be re-used in ABC, particularly if there 
has been at least one year of DFI. 
I/B 93% 
Metronomic ChT is a treatment option for patients not requiring rapid tumour response. Available 
regimens are CM (low-dose oral cyclophosphamide and methotrexate), capecitabine or oral 
vinorelbine-based regimens. Randomised trials are needed and underway to accurately compare 




Duration of each regimen and the number of regimens should be tailored to each individual patient. Expert opinion/A 96% 
Usually, each regimen (except anthracyclines) should be given until PD or unacceptable toxicity. 
What is considered unacceptable should be defined together with the patient. 
I/B 72% 
Other agents   
Bevacizumab combined with ChT as first-line therapy for ABC provides a moderate benefit in PFS 
and no benefit in OS. The absence of known predictive factors for bevacizumab efficacy renders 
recommendations on its use difficult. Bevacizumab can only therefore be considered as an option in 
selected cases and only in the first-line setting. 
ESMO-MCBS v1.1 score: 2 
I/C Yes – 42% 
No – 53% 
In green, NEW/UPDATED ABC 5 statements. 
ABC, advanced breast cancer; ChT, chemotherapy; CM, cyclophosphamide/methotrexate; consensus, percentage of panel 
members in agreement with the statement; ET, endocrine therapy; DFI, disease-free interval; ESMO-MCBS, European Society 
for Medical Oncology Magnitude of Clinical Benefit Scale; ET, endocrine therapy; GoR, grade of recommendation; HER2, 
human epidermal growth factor 2; HR, hormone receptor; LoE, available level of evidence; MBC, metastatic breast cancer; OS, 
overall survival; PD, disease progression; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PIK3CA, 
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PS, performance status; QoL, quality of life; TNBC, 




Germline BRCA status, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
(PIK3CA) for oestrogen receptor (ER)-positive ABC and programmed death-ligand 1 (PD-L1) 
for triple-negative ABC were included as important factors to take into consideration when 
making treatment decisions. Details about how to evaluate these factors and their clinical 
implications are discussed in the respective sections of the guidelines. 
The statement about the use of bevacizumab was rewritten but consensus was still not 
achieved. In the discussion, it became clear that the main reasons for this lack of consensus 
are the withdrawal of approval by the Food and Drug Administration (FDA), rendering it an 
unavailable option in the United States, and the fact that for many panellists, bevacizumab 
should not be considered a treatment option. The available data show that bevacizumab 
combined with ChT as first-line therapy for ABC provides a moderate benefit in progression-
free survival (PFS) and no benefit in OS. The ESMO-MCBS version 1.1 score for 
bevacizumab is two.36 Some experts believe it can be a good option for situations of 





Section IV: ER-positive/HER2-negative (luminal-like) ABC 
Guideline statement LoE/GoR Consensus 
ET is the preferred option for HR-positive disease, even in the presence of visceral disease, unless 
there is visceral crisis, for pre- and perimenopausal women with OFS/OFA, men (preferably with an 
LHRH agonist) and postmenopausal women. 
I/A 93% 
Many trials in ER-positive ABC have not included premenopausal women. Despite this, we 
recommend that young women with ER-positive ABC should have adequate OFS/OFA and then be 





Future trials exploring new endocrine-based strategies should be designed to allow for enrolment 




For premenopausal women, for whom ET was decided, OFS/OFA combined with additional 
endocrine-based therapy is the preferred choice. 
I/A 93% 
OFA by laparoscopic bilateral oophorectomy ensures definitive oestrogen suppression and 
contraception, avoids the potential initial tumour flare seen with an LHRH agonist and may increase 
eligibility for clinical trials. Patients should be informed of the options for OFS/OFA and decisions 




Single-agent tamoxifen is the only available endocrine option for premenopausal women who 
decline OFS/OFA, but the panel believes it is a less effective option. 
I/D 92% 
The preferred first-line agent depends on the type and duration of adjuvant ET as well as the time 




perimenopausal women with OFS/OFA, men (preferably with an LHRH agonist) and 
postmenopausal women. 
A CDK4/6 inhibitor combined with ET is the standard of care for patients with ER-positive/HER2-
negative ABC, since it achieves a substantial PFS benefit, significantly increases OS and either 
maintains or improves QoL. 
The CDK4/6 inhibitor can be combined with an AI or with fulvestrant, in de novo or recurrent ABC, 
in first or second line and in cases of primary or secondary resistance (defined as per ABC 
guidelines). 
This recommendation applies to postmenopausal women, to premenopausal women in 
combination with an LHRH agonist and to men preferably in combination with an LHRH agonist.  
I/A 97% 
The ESMO-MCBS scores for the use of a CDK4/6 inhibitor combined with ET for ABC patients vary 
according to the setting and drug. 
They are the following, with the current available data and follow-up: 
• Palbociclib + AI first line: efficacy score: 3 (PFS); no improved QoL; ESMO-MCBS v1.1 
score: 3 
• Abemaciclib + AI first line: efficacy score: 3 (PFS); no QoL reported; ESMO-MCBS v1.1 
score: 3 
• Ribociclib + AI first line postmenopausal: efficacy score: 3 (PFS); no improved QoL; ESMO-




• Ribociclib + ET first line premenopausal: efficacy score: 4 (PFS & OS); QoL improved; 
ESMO-MCBS v1.1 score: 5 
• Palbociclib + fulvestrant second line: efficacy score: 3 (PFS & OS); improved QoL; ESMO-
MCBS v1.1 score: 4 
• Ribociclib + fulvestrant first, second line: efficacy score: 4 (PFS & OS); no improvement in 
QoL; ESMO-MCBS v1.1 score: 4 
• Abemaciclib + fulvestrant second line: efficacy score: 4 (PFS & OS); no QoL benefit; ESMO-
MCBS v1.1 score: 4 
Of note, the three CDK4/6 inhibitors have not been compared head-to-head within a clinical trial. 
It remains unclear if CDK4/6 inhibitors should be preferably administered in the first- or second-line 
setting. However, the majority of panellists preferred giving a CDK4/6 inhibitor in the first-line 




There are no data supporting the use of a combination of CDK4/6 inhibitor and ET as maintenance 
therapy after ChT. 
Maintenance therapy, in this situation, should be carried out with ET alone. 
n/a/D 66% 
The addition of everolimus to an AI is a valid option for some patients [for pre- and perimenopausal 
women with OFS/OFA, men (preferably with an LHRH agonist) and postmenopausal women] 
previously exposed to or naive of (in case CDK4/6 inhibitors are not available) ET, since it 













The decision to treat must take into account the toxicities associated with this combination, the lack 
of a statistically significant OS benefit, cost and availability. 
Tamoxifen or fulvestrant can also be combined with everolimus. 
Adequate prevention, close monitoring and proactive treatment of AEs is needed, particularly in 










Everolimus and CDK4/6 inhibitors should not be used after PD on that specific agent (i.e. beyond 
progression), outside a clinical trial. 
n/a/E 74% 
Alpelisib with fulvestrant is a treatment option for patients with PIK3CA-mutated tumours (in exons 
9 or 20), previously exposed to an AI and with appropriate HbA1C levels, since it provided about 5 
months of benefit in median PFS. 
The decision to give alpelisib should take into consideration the inclusion/exclusion criteria in the 
SOLAR-1 study (i.e. pre-existing diabetes and baseline HbA1c), as well as the toxicity profile of 
alpelisib. 
Its efficacy after exposure to CDK4/6 inhibitors is unknown, since only 6% of patients in the 
SOLAR-1 trial had been previously treated with those agents. ESMO-MCBS v1.1 score: 3 
I/B 88% 
Patients receiving alpelisib in combination with ET for PIK3CA-mutated ABC should be instructed 
to take non-sedating antihistamines to prevent rash at the start of therapy. Antihistamines can be 
discontinued after 4 weeks as the risk for rash is primarily in the first 2 weeks of therapy. 
I/B 93% 
At present, no validated predictive biomarkers other than hormone receptor status exist to identify 




and none of the studied biomarkers is ready for use in clinical practice. Research efforts must 
continue. 







The combination of a nonsteroidal AI and fulvestrant as first-line therapy for postmenopausal 
patients resulted in significant improvement in both PFS and OS compared with AI alone in one 
phase III trial and no benefit in a second trial with a similar design. Notably, a suboptimal dose of 
fulvestrant was used in the study that demonstrated benefit.  
Subset analysis suggested that the benefit was limited to patients without prior exposure to 
adjuvant ET (tamoxifen). Based on these data, combination ET may be offered to some patients 
with ABC without prior exposure to adjuvant ET in cases where a CDK4/6 inhibitor will not be 
given. ESMO-MCBS v1.1 score: 2 
Comparative data between this combination and a CDK4/6 inhibitor with ET are not available. 
II/D Yes: 38%  
No: 60%  
Abstain: 2%  
The optimal sequence of endocrine-based therapy is uncertain. It depends on which agents were 
previously used [in the (neo)adjuvant or advanced settings], duration of response to those agents, 
burden of the disease, patients’ preference and availability. Available options for first and second 
line include AI/fulvestrant + CDK4/6 inhibitor, AI/tamoxifen/fulvestrant + everolimus, fulvestrant + 
alpelisib (for PIK3CA-mutated tumours), AI, tamoxifen, fulvestrant. This applies to pre- and 





Options for treatment of ER-positive disease beyond second line include single agents not 
previously used (NSAI, SAI, tamoxifen, fulvestrant, megestrol acetate, low-dose oestrogen). Single-
agent abemaciclib is also a potential option. 
Challenging a patient with an agent on which the disease previously progressed after an initial 
response is occasionally considered, but there are no robust data to support this approach. This 
applies to pre- and perimenopausal women with OFS/OFA, men (preferably with an LHRH agonist) 










Trials comparing the different combinations of endocrine + targeted agents with single-agent ChT 
are ongoing. 
Initial results from phase II and III randomised trials comparing combinations of endocrine + 
targeted agents to single-agent ChT do not show significant differences in terms of efficacy, and 
the former compares favourably in terms of safety. 
II/B Not voted 
Concomitant ChT and ET has not shown a survival benefit and should not be performed outside a 
clinical trial. 
II/D 100% 
Endocrine treatment after ChT (maintenance ET) to maintain benefit is a reasonable option, though 
it has not been properly assessed in randomised trials. 
III/B 88% 
In green, NEW/UPDATED ABC 5 statements.  
ABC, advanced breast cancer; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; ChT, chemotherapy; consensus, 
percentage of panel members in agreement with the statement; ER, oestrogen receptor; ESMO-MBCS, European Society for 
Medical Oncology Magnitude of Clinical Benefit Scale; ET, endocrine therapy; GoR, grade of recommendation; HER2, human 
epidermal growth factor receptor 2; HR, hormone receptor; LHRH, luteinising hormone-releasing hormone; LoE, level of 
evidence; mTOR, mammalian target of rapamycin; n/a, not applicable; NSAI, non-steroidal aromatase inhibitor; OFS, ovarian 
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function suppression; OFA, ovarian function ablation; OS, overall survival; PD, progressive disease; PIK3CA, 
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PFS, progression-free survival; QoL, quality of life; SAI, 




The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors 
combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative 
ABC in view of the OS benefit seen in several trials,37-43 both in the first- and second-line 
settings, substantial PFS benefit and good toxicity profile.37-58 These agents can be combined 
with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, 
in first or second line, in cases of primary or secondary resistance, in postmenopausal and 
premenopausal women (the latter with OFS/OFA), and in men (preferably with an LHRH 
agonist). Of note, the combination of tamoxifen and ribociclib led to increased cardiotoxicity 
(arrhythmia) and should be avoided.37 Notwithstanding these results, the panel acknowledges 
that there is a small group of patients who can be treated with ET alone; although clear 
identification of these patients is not possible at this time, factors such as limited burden of 
metastatic disease and features of less aggressive biology [i.e. very long disease-free interval 
(DFI)] can help with this identification. There are currently no biomarkers to enable accurate 
identification of these patients. The ESMO-MCBS scores provided are based on available 
data at the time of publication of this manuscript. These scores may change in the future, with 
new data being published, and updates will be provided on the ESMO website. 
The SOLAR-1 phase III, randomised, placebo-controlled trial evaluated the role of 
alpelisib, an oral inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) isoform, in 
combination with fulvestrant, for postmenopausal women and men who had previously been 
treated with an AI.59 In the PIK3CA-mutated cohort, alpelisib provided a PFS benefit of 11.0 
months versus 5.7 months [hazard ratio (HR) for progression or death: 0.65; 95% confidence 
interval (CI) 0.50–0.85, P < 0.001). OS data are not yet available. Toxicity was substantially 
increased in the alpelisib arm, especially hyperglycaemia, rash, gastrointestinal (GI) 
complaints (nausea, vomiting, loss of appetite, mucositis, diarrhoea) and fatigue, which lead 
to dose reductions/interruptions in around 70% of patients and discontinuations in 25%. 
Alpelisib, in combination with fulvestrant, was EMA-approved for use in this setting in July 
2020. The ESMO-MCBS for alpelisib in combination with fulvestrant was established at three 
because this scoring system does not consider the percentages of dose alterations and/or 
discontinuations as a marker of important toxicity, which in the opinion of the ABC panel, is a 
shortcoming of the v.1.1. of the scale (scheduled to be changed in the upcoming version 1.2 
of the ESMO-MCBS). In view of the balance between efficacy and toxicity, it is crucial to 
carefully select patients who may be candidates for this treatment, considering the 
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inclusion/exclusion criteria in SOLAR-1 and comorbidities, especially pre-existing diabetes 
and baseline HbA1c levels. It is also recommended that patients take non-sedating 
antihistamines to prevent rash at the start of therapy;60,61 these can be discontinued after 4 
weeks as the risk of rash is primarily in the first 2 weeks of therapy. The ABC panel considers 
alpelisib a treatment option for patients with ER-positive/HER2-negative PIK3CA-mutated 
ABC, but in view of the higher benefit provided by CDK4/6 inhibitors, alpelisib plus ET should 
be used after CDK4/6 plus ET. Only 20 patients (6%) in SOLAR-1 had been previously 
exposed to a CDK4/6 inhibitor. However, this is a common issue in oncology, where 
standards of care might change during the course of a trial. Furthermore, the large phase II 
BYLive trial has shown efficacy of alpelisib after CDK4/6 inhibitor use.61 Based on all of the 
available data, the ABC panel acknowledges that no data exist to determine the best 
sequence of therapies for this ABC subtype but believes that the most adequate sequence, in 
settings where availability of all drugs exist, is the use of a CDK4/6 inhibitor plus ET as first 
line, followed by alpelisib plus ET in patients with PIK3CA-mutated tumours or everolimus 





Section V: HER2-positive ABC 
Guideline statement LoE/GoR Consensus 
Anti-HER2 therapy should be offered early (as first line) to all patients with HER2-positive ABC, 
except in the presence of contraindications to the use of such therapy. 
I/A 98% 
Patients progressing on an anti-HER2 therapy combined with a cytotoxic or endocrine agent 
should be offered additional anti-HER2 therapy with subsequent treatment, except in the 
presence of contraindications, since it is beneficial to continue suppression of the HER2 
pathway. 
The choice of the anti-HER2 agent will depend on country-specific availability, the specific anti-
HER2 therapy previously administered and the relapse-free interval. The optimal sequence of all 
available anti-HER2 therapies is currently unknown. 










In patients achieving a complete remission, the optimal duration of maintenance anti-HER2 
therapy is unknown and needs to be balanced against treatment toxicity, logistical burden and 
cost. Stopping anti-HER2 therapy after several years of sustained complete remission may be 





Patients who have received any type of (neo)adjuvant anti-HER2 therapy should not be 





For highly selected patientsa with ER-positive/HER2-positive ABC, for whom ET + anti-HER2 
therapy was chosen as first-line therapy, dual anti-HER2 blockade (with either pertuzumab + 
trastuzumab or lapatinib + trastuzumab) can be used since it provides a benefit in PFS. This 
decision must be balanced against the higher side effects, higher costs and lack of OS benefit 
so far, as compared with ET + anti-HER2 monotherapy. 
I/B 80% 
For patients with ER-positive/HER2-positive ABC, for whom ChT + anti-HER2 therapy was 
chosen as first-line therapy and provided a benefit, it is reasonable to use ET + anti-HER2 
therapy as maintenance therapy after stopping ChT, although this strategy has not been studied 
in randomised trials. 
Duration of maintenance therapy should be until progression, unacceptable toxicity or patient 
request, and needs to be evaluated in clinical trials. 
There are no data to decide between single-agent anti-HER2 or dual blockade to combine with 
maintenance ET after stopping ChT in ER-positive/HER2-positive ABC. 
n/a/B 80% 
In the first-line setting, for HER2-positive ABC previously treated (in the adjuvant setting with DFI 
>12 months) or untreated with trastuzumab, combinations of ChT + trastuzumab are superior to 
combinations of ChT + lapatinib in terms of PFS and OS. 
I/A 95% 
The standard first-line therapy for patients previously untreated with anti-HER2 therapy is the 
combination of ChT + trastuzumab and pertuzumab because it has proven to be superior to ChT 
+ trastuzumab in terms of OS in this population. ESMO-MCBS v1.1 score: 4 
I/A 86% 
For patients previously treated [in the (neo)adjuvant setting] with anti-HER2 therapy, the 






Few (88) of these patients were treated in the CLEOPATRA trial and all with a trastuzumab-free 
interval >12 months. 
 
There are currently no data supporting the use of dual blockade with trastuzumab + pertuzumab 
and ChT beyond progression (i.e. continuing dual blockade beyond progression) and therefore 
dual blockade should not be given beyond progression outside clinical trials. 
I/E 86% 
In a HER2-positive ABC patient previously untreated with the combination of ChT + trastuzumab 
+ pertuzumab, it is acceptable to use this treatment after first line. 
II/B 76% 
After first-line trastuzumab-based therapy, T-DM1 provides superior efficacy relative to other 
HER2-based therapies in the second line (versus lapatinib + capecitabine) and beyond (versus 
treatment of physician’s choice).  
T-DM1 should be preferred in patients who have progressed through at least one line of 
trastuzumab-based therapy, because it provides an OS benefit. ESMO-MCBS v1.1 score: 4 
I/A 88% 
In case of progression on trastuzumab-based therapy, the combination trastuzumab + lapatinib 
is a reasonable treatment option for some patients. ESMO-MCBS v1.1 score: 4 






The combination of neratinib + capecitabine was compared with lapatinib + capecitabine as third 
line or beyond therapy for HER2-positive ABC, showing a marginal benefit in PFS, and with no 
significant difference in the co-primary end point of OS. There was no comparator arm with 




lapatinib + capecitabine. Therefore, the combination of neratinib + capecitabine is not 
recommended for routine clinical practice. 
ESMO-MCBS: No manuscript publication; precludes scoring. 
Additional studies are needed to clearly establish the potential role of this combination in the 
treatment of brain metastases, as well as the role of neratinib for ABC. 
Trastuzumab deruxtecan (DS-8201) showed important activity in a phase II study in heavily 
pretreated patients with HER2-positive ABC (median lines of therapy: 6), and is a treatment 
option in this setting, where approved. Pulmonary toxicity (interstitial lung disease/pneumonitis) 
can be fatal and requires active surveillance and proper management. ESMO-MCBS v1.1 
score: 2 
II/B 98% 
Dual blockade with tucatinib + trastuzumab + capecitabine showed a small benefit in median 
PFS (2 months) and median OS (4 months) over trastuzumab + capecitabine in patients 
previously treated with trastuzumab, pertuzumab and T-DM1, including patients with brain 
metastases, at the expense of higher toxicity (i.e. diarrhoea). If approved, it can be considered a 
treatment option in this setting. ESMO-MCBS v1.1 score: 3. 
II/B 98% 
Margetuximab + ChT showed only a small PFS benefit (1 month) when compared with 
trastuzumab + ChT for patients pretreated with pertuzumab and T-DM1, and cannot therefore be 
recommended for routine clinical practice. ESMO-MCBS: No manuscript publication; 
precludes scoring. 
The role of CD16A genotype as a predictor of anti-HER2 antibody efficacy and selection of anti-








Regarding the ChT component of HER2-positive ABC treatment: 
When pertuzumab is not given, first-line regimens for HER2-positive ABC can include 
trastuzumab combined with vinorelbine or a taxane. Differences in toxicity between these 
regimens should be considered and discussed with the patient in making a final decision. 








For later lines of therapy, trastuzumab can be administered with several ChT agents, including 
but not limited to, vinorelbine (if not given in first line), taxanes (if not given in first line), 
capecitabine, eribulin, liposomal anthracyclines, platinums, gemcitabine or metronomic CM. The 
decision should be individualised and take into account different toxicity profiles, previous 
exposure, patient preferences and country availability. 
II/A 91% 
ChT agents to combine with a dual blockade of trastuzumab + pertuzumab are docetaxel [I/A] or 
paclitaxel [I/B]. Also possible are vinorelbine [II/A], nab-paclitaxel [II/B], capecitabine [I/A] and 




In green, NEW/UPDATED ABC 5 statements. 
ABC, advanced breast cancer; ChT, chemotherapy; CM, cyclophosphamide and methotrexate; consensus, percentage of panel 
members in agreement with the statement; DFI, disease-free interval; ESMO-MCBS, European Society for Medical Oncology 
Magnitude of Clinical Benefit Scale; ET, endocrine therapy; GoR, grade of recommendation; HER2, human epidermal growth 
factor receptor 2; LoE, level of evidence; MBC, metastatic breast cancer; n/a, not applicable; OS, overall survival; PFS, 
progression-free survival; T-DM1, trastuzumab emtansine. 
a See definition in ABC 4.62 
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After years of relatively limited progress in the management of advanced HER2-positive 
breast cancer, the last year has enriched our armamentarium of drugs effective in this ABC 
subtype. A number of new representatives of the most relevant classes of drugs – monoclonal 
antibodies, antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) – have 
demonstrated activity superior to previously-available options in patients pretreated with 
standard first- and second-line treatments. 
Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination 
with capecitabine and trastuzumab in a population of ABC patients pretreated with 
trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement 
of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42–0.71, P < 0.001) and 
OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI 0.50–0.88; P = 0.005) 
compared with patients treated with capecitabine/trastuzumab/placebo.63 This was achieved 
at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of 
grade ≥3, but did not lead to frequent treatment discontinuation. Importantly, a reduction in 
the risk of CNS progression or death by 69% was observed in patients with stable brain 
metastases, while a confirmed objective response rate of 47% and a reduced risk of death by 
51% were observed in patients with active brain metastases.64 
Trastuzumab deruxtecan (DS-8201), an ADC composed of trastuzumab, a cleavable 
tetrapeptide-based linker and a cytotoxic topoisomerase I inhibitor, demonstrated a response 
rate of 60.6% (95% CI 53.4–68.0) and an unprecedented median PFS of 16.4 months (95% 
CI 12.7 – not reached) in a phase II study of heavily pretreated patients (median six lines, 
range 2–27 lines, including trastuzumab and T-DM1).65 Trastuzumab deruxtecan was 
associated with a 13.6% risk of interstitial lung disease (ILD)/pneumonitis, fatal in 2.2% of 
cases, which needed appropriate and rapid diagnosis and treatment. For the safe utilisation of 
this compound in clinical practice (i.e. outside clinical trials), active surveillance and education 
regarding the signs and symptoms, for both patients and health care professionals, are crucial 
to enable rapid diagnosis and management. Confirmatory results from phase III studies are 
eagerly awaited and needed to accurately determine the role of this very promising drug in 
the HER2-positive ABC setting. 
Both compounds are FDA-approved and await evaluation by the EMA. 
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Another two agents which demonstrated formally positive (although clinically of 
questionable value) trial results in pretreated HER2-positive ABC patients are margetuximab 
(a monoclonal antibody) and neratinib. Margetuximab resulted in only a 0.9 month PFS 
prolongation (HR 0.76; 95% CI 0.59–0.98, P = 0.033) compared with trastuzumab (both 
combined with ChT of physician’s choice), no OS benefit and a good toxicity profile.66 The 
potential role of CD16A genotype as a predictor of anti-HER2 antibody efficacy was explored 
and initial results were encouraging and deserve further evaluation. Margetuximab is currently 
under evaluation by the FDA and EMA and is not yet approved for use in ABC. 
Neratinib provided a small reduction in the risk of disease progression of 24% (95% CI 
0.63–0.93; P = 0.006, medians not provided), a marginal difference in PFS and no impact on 
overall survival (co-primary end point) compared with lapatinib (both in combination with 
capecitabine), at the cost of increased toxicity.67 Furthermore, the NALA study has a severe 
limitation of not having a comparator arm with trastuzumab plus capecitabine, which was 
previously shown to provide superior OS to lapatinib plus capecitabine in the first- and 
second-line settings.68 As of July 2020, neratinib in combination with capecitabine is FDA-
approved for pretreated metastatic HER2-positive breast cancer, but is still under evaluation 
by the EMA in this setting. 
It is especially important to emphasise that there are no comparative data between 
these four new anti-HER2 agents and that the question regarding the optimal sequence of 





Section VI:  Tiple negative ABC 
Guideline statement LoE/GoR Consensus 
In triple-negative ABC patients (regardless of BRCA status) previously treated with anthracyclines 
with or without taxanes in the (neo)adjuvant setting, carboplatin demonstrated comparable efficacy 
and a more favourable toxicity profile compared with docetaxel and is, therefore, an important 
treatment option. 
I/A 91% 
For non-BRCA-associated triple-negative ABC, there are no data supporting different or specific 
ChT recommendations, besides platinum. Therefore, all ChT recommendations for HER2-negative 
disease also apply for triple-negative ABC. 
I/A 98% 
The AR is a potential target in triple-negative ABC. There are, however, no standardised methods 
to assay AR. Limited data suggest a low level of efficacy for AR antagonist agents such as 
bicalutamide and enzalutamide. At this time, these agents should not be used in routine clinical 
practice. 
More definitive trials are needed, and research efforts must continue to optimise and standardise 
the determination of AR. 
II/D 85% 
Atezolizumab + nab-paclitaxel is an option for first-line therapy for PD-L1-positivea triple-negative 
ABC, either de novo or at least 12 months since (neo)adjuvant ChT. ESMO-MCBS v1.1 score: 3 
I/B 95% 
Checkpoint inhibitor monotherapy in later lines for triple-negative ABC is not recommended due to 
low response rates. 
I/E 89% 
Several ongoing trials are evaluating the role of immunotherapy in other ABC subtypes (non-




Immunotherapy, with a checkpoint inhibitor, for any biological subtype of ABC should not be used 
in routine clinical practice outside clinical trials. Several ongoing trials are evaluating the role of this 
type of treatment in all ABC subtypes. 
III/D 85% 
In green, NEW ABC 5 statements.  
ABC, advanced breast cancer; AR, androgen receptor; ChT, chemotherapy; consensus, percentage of panel members in 
agreement with the statement; ESMO-MCBS, European Society for Medical Oncology Magnitude of Clinical Benefit Scale; 
GoR, grade of recommendation; HER2, human epidermal growth factor receptor 2; LoE, level of evidence; n/a, not applicable; 
PD-L1, programmed death-ligand 1; T-DM1, trastuzumab emtansine; TNBC, triple-negative breast cancer.  





Recent years have brought about the beginning of a significant change in the approach to 
triple-negative ABC with the recognition that both clinically and molecularly this is not one but 
many diseases. For most patients, ChT remains the only available non-investigational 
systemic treatment option for non-BRCA-mutated triple-negative ABC, with no specific 
recommendations regarding types of agents, with the possible exception of platinum 
compounds for patients with BRCA-mutated triple-negative ABC. However, immunotherapy 
has emerged as an option in the first-line setting for those with PD-L1 ≥1% in immune cells. 
IMpassion-130 is a phase III randomised, placebo-controlled trial that compared atezolizumab 
and nab-paclitaxel to nab-paclitaxel alone.69 The study had co-primary end points of PFS and 
OS in the intention-to-treat (ITT) population and had a hierarchal design that allowed for 
evaluation of OS in the PD-L1-positive population if the OS in the ITT population was 
significantly improved from the addition of atezolizumab. In the ITT population, atezolizumab 
provided a benefit in PFS of 7.2 versus 5.5 months with a HR of 0.8 (95% CI 0.69–0.92, P = 
0.002). In the PD-L1 positive group, atezolizumab provided a PFS benefit of 7.5 versus 5 
months with a HR of 0.62 (95% CI 0.49–0.78, P < 0.001). In the ITT population, there was no 
significant benefit in OS with the addition of atezolizumab; median OS was 21.3 months 
versus 17.6 months (HR 0.84; 95% CI 0.69–1.02, P = 0.08). However, despite the hierarchal 
statistical design that precluded an OS analysis in the PD-L1-positive population if the OS in 
the ITT population was not significant, an analysis was conducted and presented, and 
showed an OS of 25 months versus 15.1 months favouring the atezolizumab arm. Based on 
these data, atezolizumab in combination with nab-paclitaxel was approved and may be 
considered an option in the first-line setting for de novo advanced/metastatic disease or 
disease that has developed at least 12 months after completion of (neo)adjuvant ChT, in 
tumours that have PD-L1 expression ≥1% based on staining of the immune cells using the 
companion test of SP142 PD-L1 immunohistochemical assay (Ventana Medical systems).69 
Recently, these data were updated showing a PFS difference of 2.5 months and an OS 
difference of 7 months in the PD-L1-positive population.70 More recently, at ASCO 2020 
virtual meeting, data from the KEYNOTE-355 trial was presented. KEYNOTE-355 was a 
randomised double-blind, phase III trial evaluating the role of pembrolizumab plus ChT for 
previously untreated triple-negative ABC, which showed an improvement in PFS with the 
addition of pembrolizumab (9.7 versus 5.6 months; HR 0.65; CI 0.49–0.86, P = 0.0012) for 
PD-L1-positive (combined positive score ≥10), triple-negative ABC.71 
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Checkpoint inhibitor monotherapy in later lines for triple-negative ABC is not 
recommended due to low response rates, as seen in the KEYNOTE-199 trial.72 In patients 
with triple-negative ABC and a germline BRCA mutation, a poly-adenosine diphosphate 
ribose polymerase (PARP) inhibitor is a preferred treatment option (please refer to section on 
hereditary ABC). In the small proportion of patients with both PD-L1-positive disease and 
BRCA1/2 mutations, the selection of immunotherapy or a PARP inhibitor for first-line 
treatment remains an area of debate. 
No further data to support antiandrogen therapy for triple-negative ABC with 
expression of the androgen receptor has been published since ABC 4 and therefore it cannot 
be recommended for routine clinical use outside a clinical trial. 
Sacituzumab govitecan-hziy has demonstrated promising activity in advanced lines for 
triple-negative ABC in a phase I/II study of 108 patients who had received a range of 2–10 
prior treatments for metastatic disease.73 The overall response rate was 33.3% (95% CI 24.6–
43.1), with a median duration of response of 7.7 months (95% CI 4.9–10.8). Of the patients 
with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 
months and 16.7% maintained their response for ≥12 months. Based on these preliminary 
results, the FDA has granted accelerated approval. However, phase III results are needed to 





Section VII: hereditary ABC 
Guideline statement LoE/GoR Consensus 
Genetic testing   
For ABC patients, results from germline genetic testing have therapeutic implications and should 
therefore be performed as early as possible. 
Appropriate counselling should be provided to patients and their families if a pathogenic germline 
mutation is found. 
I/A 88% 
At present, only germline mutations in BRCA1/2 have proven clinical utility and therapeutic 
impact. 
I/A 100% 
Testing for other additional moderate- to high-penetrance genes may be considered, if deemed 
appropriate by the geneticist/genetic counsellor, in particular because they may have 
implications for family members. However, it must be clarified to the patient that at present, a 
mutation in another moderate-/high-penetrance gene has no direct clinical implications for the 
patients themselves in the setting of ABC. 
Expert opinion/C 100% 
The therapeutic implications of somatic BRCA1/2 mutations in breast tumours need to be further 
explored within a research setting and should not be used for decision making in routine clinical 
practice. 
n/a/E 83% 
BRCA-associated ABC   
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In patients with gBRCA-associated triple-negative ABC or endocrine-resistant ABC previously 
treated with an anthracycline with or without a taxane (in the adjuvant and/or metastatic setting), 
a platinum regimen is the preferred ChT option, if not previously administered. 
All other ChT recommendations are similar to those for sporadic ABC.  
I/A 86% 
For patients with a gBRCA mutation, single-agent PARPi (olaparib or talazoparib) is a preferred 
treatment option for those with triple-negative ABC. 
In ER-positive gBRCA-associated ABC, the optimal sequence between a PARPi and ET with or 
without a CDK4/6 inhibitor is unknown. Given the OS benefit seen with CDK4/6 inhibitors, the 
panel recommends their use before a PARPi. 
Single-agent PARPis (olaparib or talozaparib) are associated with a PFS benefit, improvement in 
QoL and a favourable toxicity profile. Results suggest that any benefit in OS may be limited to 
the first-line setting. 










It is unknown how PARPis (olaparib or talazoparib) compare with platinum compounds in this 
setting, the optimal use with platinum (combined or sequential) and their efficacy in tumours 
progressing after platinum. 




BROCADE3 was the first phase 3 trial testing a PARPi (veliparib) in gBRCA-mutated MBC that 
included a platinum. Initial presentation of results showed a small benefit in PFS (1.9 months). 
However, durable PFS at 3 years was seen in a significant minority (one in four patients) during 




with ChT-free time. Mature OS data are needed before this regimen can be recommended for 
routine clinical practice. 
ESMO-MCBS: No manuscript publication; precludes scoring. 
In green, NEW ABC 5 statements. 
ABC, advanced breast cancer; CDK, cyclin-dependent kinase; ChT, chemotherapy; consensus, percentage of panel members 
in agreement with the statement; ESMO-MCBS, European Society for Medical Oncology Magnitude of Clinical Benefit Scale; 
ET, endocrine therapy; GoR, grade of recommendation; HER2, human epidermal growth factor receptor 2; LoE, level of 
evidence; MBC, metastatic breast cancer; n/a, not applicable; OS, overall survival; PARPi, poly-adenosine diphosphate ribose 





For ABC patients, results from germline genetic testing for a mutation in BRCA1/2 have 
therapeutic implications and should therefore be discussed with the patient and carried out as 
early as possible. Genetic testing should be guided by national/international guidelines,74 
should be proposed to all male breast cancer patients and may also be considered for all 
patients with triple-negative disease. Genes to be tested depend on personal and family 
history. However, at present, only germline mutations in BRCA1/2 have any clinical utility and 
therapeutic impact. Although BRCA1/2 are the most frequently mutated genes, testing for 
other additional moderate- to high-penetrance genes may be considered, if deemed 
appropriate by the geneticist/genetic counsellor, but it must be clarified to the patient that, at 
present, a mutation in another moderate- to high-penetrance gene has limited clinical 
implications in the setting of ABC – this is an area of research with several ongoing clinical 
trials and emerging phase II data suggesting a benefit of PARP inhibitors (PARPis) in patients 
with germline PALB2 mutations.75 
Since ABC 4, further data from the OlympiAD study suggested an OS benefit for 
olaparib when given in the first-line setting, with a median OS of 22.6 months versus 14.7 
months (HR 0.51; 95% CI 0.29–0.90, P = 0.02) in a subgroup analysis of predefined 
stratification subgroups,76 lending further support to existing data for a PFS benefit with 
olaparib in the ITT population of the study.77 
The EMBRACA study78 had a similar design to the OlympiAD study, comparing 
talazoparib with ChT monotherapy per physician’s choice (capecitabine, eribulin, vinorelbine 
or gemcitabine). Most patients had not received prior platinum-based therapy. At a median 
follow-up of 11.2 months, PFS was longer in the talazoparib arm (8.6 months versus 5.6 
months, HR 0.54; 95% CI 0.41–0.71, P < 0.0001). Recently, at the American Association for 
Cancer Research (AACR) 2020 virtual meeting, an update was presented and no benefit was 
demonstrated in OS.79 However, it is worth noting that nearly 60% of patients in the control 
arm went on to receive a PARP inhibitor or platinum agent. At the ESMO 2019 annual 
meeting, data was presented from the BROCADE3 study – the first phase III study in ABC 
comparing the addition of a PARPi (veliparib) to a platinum-containing regimen (paclitaxel and 
carboplatin) for germline BRCA-mutated ABC.80 The study demonstrated a PFS benefit 
favouring the veliparib arm, with a median PFS of 14.5 versus 12.6 months, HR 0.71; 95% CI 
0.57–0.88, P = 0.002) and a suggestion of sustained response at 2 and 3 years favouring the 
arm that was receiving maintenance veliparib but at the expenses of significant toxicity. Peer-
49 
 
reviewed publication of the data is awaited, and further data are needed before this 
combination can be recommended for germline BRCA-mutated ABC. 
Further studies are also needed to clarify the value of PARPis in platinum-resistant 





Section VIII: precision medicine 
Guideline statement LoE/GoR Consensus 
Multigene panels, such as those obtained using NGS or other technology on tumour DNA have not 
yet proven beneficial in clinical trials for ABC; their impact on outcome remains undefined and should 
not be used in routine clinical practice. 
For patients who are suitable to participate in clinical trials of novel therapies and are readily 
able/motivated to attend a centre with relevant clinical trials, NGS testing may be used in the context 
of prospective molecular triage programmes to select patients for therapeutic trials. 
Specific tests (as distinguished from broad mutation profiles) are useful and discussed in separate 
statements; others may play a role in the future as the medicines they are linked with achieve 
regulatory approval. 
I/D 83% 
ctDNA assessment is not recommended for demonstration of disease progression. I/D 97% 
ctDNA assessment is an option for the detection of PIK3CA mutations for selection of patients 
eligible for alpelisib. 
II/A 93% 
If treatment with the PI3K inhibitor, alpelisib, is available, patients should be tested for PIK3CA 
mutation (in exon 9 and 20) in a tissue (metastasis or primary) and/or in ctDNA testing in blood. 
Patients who do not have an available archival tissue sample and have an uninformative result using 




ESR1 mutation status assessment is not ready for routine clinical practice use and is not 
recommended, either for demonstration of disease progression or selection of ET (such as a switch 
from AI to fulvestrant). 
I/D 90% 
PD-L1 status should be tested in cases of first-line triple-negative ABC if treatment with immune 
checkpoint inhibitors is available.  
I/A 97% 
PD-L1 status is the companion test for the use of the combination of atezolizumab and taxane as 
first-line therapy for triple-negative ABC, using IHC with the SP142 antibody (Ventana) and a cut-off 
of 1% of positive staining on immune cells. 
I/A 97% 
Patients with low (1%–10%) ER- (and PgR-) positive, HER2-negative ABC should not be considered 
for ET exclusively. 
Patients with low (1%–10%) ER- (and PgR-) positive, HER2-negative ABC can be considered as 
patients with triple-negative ABC for clinical trials. 
III/B 95% 









If an ABC patient presents with a tumour with an NTRK fusion, treatment with a TRKi is a possible 
consideration. 





Patients must be informed about the amount of data available for ABC specifically. Research on the 
best companion diagnosis tools and techniques is needed. Prospective registries should be created 
to collect data from all patients treated with these innovative approaches after proper consent. 
Insufficient 
data: 47% 
In green, NEW ABC 5 statements. 
ABC, advanced breast cancer; consensus, percentage of panel members in agreement with the statement; ctDNA, circulating 
tumour DNA; ER, oestrogen receptor; ET, endocrine therapy; GoR, grade of recommendation; HER2, human epidermal growth 
factor receptor 2; IHC, immunohistochemistry; LoE, level of evidence; MMR-D, mismatch repair deficiency; MSI-H, 
microsatellite instability-high; NGS, next-generation sequencing; NTRK, neurotrophic receptor tyrosine kinase; PD, disease 
progression; PD-1, programmed cell death protein 1; PgR, progesterone receptor; PI3K, phosphoinositide 3-kinase; PIK3CA, 





Circulating DNA assays assess cell-free tumour DNA qualitatively and quantitatively for 
molecular alterations in a non-invasive fashion from a simple blood sample. Different 
technologies are available from single-gene assay by quantitative polymerase chain reaction 
(qPCR) to whole genome sequencing by next-generation sequencing (NGS).81,82 
Standardisation is a critical point, especially for NGS-based analysis. There is insufficient 
evidence of clinical validity and utility for the majority of circulating tumour DNA (ctDNA) 
assays in advanced cancer.83 Thus, ctDNA assessment is not recommended for 
demonstration of disease progression in ABC. However, for single biomarkers using targeted 
assays, ctDNA assessment is an option for the detection of PIK3CA mutations for selection of 
patients eligible for alpelisib. 
The progress of precision medicine has helped to describe around 40 recurrent driver 
alterations in breast cancer. ESMO has recently developed a Scale for Clinical Actionability of 
molecular Targets (ESCAT) to interpret the targetability of genomic alterations in the context 
of clinical practice.84 The aim is to help clinicians to prioritise treatment after NGS results. The 
tool ranks genomic alterations in tiers, based on the strength of their clinical validation (from I 
to V and X). ERBB2 amplification, germline deleterious BRCA 1 and 2 mutations and PIK3CA 
mutations are all classified as tier IA. The majority of PIK3CA mutations affect hot spots i.e. 
the three most frequent in exons 9 and 20 (exon 9: E542K, E545K, helicase domain; exon 20: 
H1047R, kinase domain). They are present in up to 40% of metastatic luminal breast cancer. 
The mutations activate the alpha isoform of PI3K and drive oncogenicity. There were three 
sub-analyses of the SOLAR-1 trial59 which showed that the benefit seen with alpelisib was 
independent of the type of PIK3CA test, i.e. tissue biopsy from the primary or the metastasis, 
liquid or tissue biopsy, NGS or targeted PCR test.85-87 If treatment with the PI3K inhibitor, 
alpelisib, is available, patients should be tested for PIK3CA mutation (in exons 9 and 20) in 
tissue (metastasis or primary) and/or by ctDNA testing in blood. Patients who do not have an 
available archival tissue sample and have an uninformative result using the liquid biopsy test 
could consider undergoing a new biopsy for PIK3CA mutation testing. 
Acquisition of ESR1 mutations, frequent in ABC patients previously treated by AIs 
(20%–40%), is one of the mechanisms of resistance to hormonal therapies. The consequence 
is a ligand-independent, constitutive activity of ER. To assess the impact of the presence of 
ESR1 mutations in plasma samples of ABC patients, the post hoc prospective-retrospective 
analysis of the SOFEA trial failed to demonstrate a statistically significant impact of ESR1 
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mutations on response to AI versus fulvestrant (interaction test between the two regimens P = 
0.07). The analysis of the PALOMA-3 trial showed that the presence of plasma ESR1 
mutations had no impact on response to palbociclib (interaction test between the two 
regimens P = 0.74).88 Despite promising preclinical data and statistical trends, the ESCAT 
scale for ESR1 mutations is tier II.84 Therefore, ESR1 mutation status assessment is not 
ready for routine clinical use and is not recommended, either for demonstration of disease 
progression or selection of hormonal treatment (such as a switch from AI to fulvestrant). 
Increased counts of tumour-infiltrating lymphocytes (TILs) are prognostic for survival in 
TNBC, making this disease a potential target for immunotherapy.89 Based on the results of 
the IMpassion-130 trial,69 atezolizumab was approved with the Ventana PD-L1 (SP142) assay 
as a companion diagnostic immunohistochemistry (IHC) assay. Therefore, PD-L1 status 
should be tested in cases of first-line triple-negative ABC if treatment with immune checkpoint 
inhibitors is available. Several IHC assays are available to assess PD-L1 status.90 SP-263 
(Ventana) and 22-C3 (Dako), both of which are widely used in pathology laboratories for other 
tumour types, have been evaluated for their clinical validity in the context of the IMpassion-
130 trial but failed to reproduce SP-142 clinical validity.91 Thus, PD-L1 status by SP142 is the 
companion test for the use of atezolizumab in combination with a taxane for first-line therapy 
in triple-negative ABC, with a cut-off of 1% positive staining on immune cells. It is critical for 
medical oncologists and pathologists to know the available assays and their relevance to the 
therapeutic options in order to develop a workflow for IHC testing. 
Tumours with staining of ER <1% and progesterone receptor (PgR) <1% and with 
HER2-negative results by IHC and/or in situ hybridisation are defined as TNBC.92 Patients 
with a low (1%–10%) expression of hormone receptors and HER2-negative account for 2%–
3% of breast cancers. They may share morphological (high grade, poor differentiation)93 and 
biological features94,95 with TNBC and experience a similarly poor survival.96,97 A meta-
analysis assessing the survival benefit of ET for ER-low (<10%) primary breast cancer 
showed lower endocrine responsiveness compared with ER-positive tumours [odds ratio (OR) 
0.52, P = 0.034].98 Recently, the ASCO-College of American Pathologists (CAP) guidelines 
acknowledged that patients with tumours between 1% and 10% of ER staining represent a 
new reporting category, stipulating the lack of data concerning benefit from ET and the 
proximity to ER-negative breast cancer of this patient group.99 We recommend that this 
strategy is also adopted for ABC patients with a low ER-positive status. 
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Section IX: specific sites of metastases 
Guideline statement LoE/GoR Consensus 
Bone metastases   
Radiological assessments are required in patients with persistent and localised pain due to bone 
metastases to determine whether there are impending or actual pathological fractures. If a fracture 
of a long bone or vertebrae is likely or has occurred, an orthopaedic assessment is required as the 
treatment of choice may be surgical stabilisation, which is generally followed by RT. In the 
absence of a clear fracture risk, RT is the treatment of choice. 
I/A 96% 
Neurological symptoms and signs which suggest the possibility of spinal cord compression must 
be investigated as a matter of urgency. This requires a full radiological assessment of the 
potentially affected area as well as adjacent areas of the spine. MRI is the method of choice. An 
emergency surgical opinion (neurosurgical or orthopaedic) may be required for surgical 
decompression. If no decompression/stabilisation is feasible or indicated, emergency RT is the 
treatment of choice and vertebroplasty is also an option. 
I/B 100% 
Regarding the use of bone-targeted agents (bisphosphonate, denosumab), the ABC panel 
endorses the ESMO CPG100 related to this subject. 
n/a 100% 
Brain metastases   
Patients with a single or a small number of potentially resectable brain metastases should be 





If surgery/radiosurgery is performed it may be followed by WBRT, but this should be discussed in 
detail with the patient, balancing the longer duration of intracranial disease control and the risk of 
neurocognitive effects. 
I/C 72% 
HER2-positive ABC and brain metastases   
Because patients with HER2-positive ABC and brain metastases can live for several years, 
consideration of long-term toxicity is important and less toxic local therapy options (e.g. 
stereotactic RT) should be preferred to WBRT, when available and appropriate (e.g. in the setting 
of a limited number of brain metastases). 
I/A 89% 
In patients with HER2-positive ABC who develop brain metastases with stable extracranial 
disease, systemic therapy should not be changed. 
I/D 95% 
For patients with HER2-positive ABC where brain metastases are the only site of recurrence, the 
addition of ChT to local therapy is not known to alter the course of the disease and is not 
recommended. 






For patients with HER2-positive ABC with progressive brain metastases as the predominant site of 
disease burden, if no further relevant local therapy options are available, a change in systemic 
therapy is a reasonable option, preferably in clinical trials. 
III/A 85% 
Radionecrosis after stereotactic RT for brain metastases is an uncommon complication that may 
occur, especially with longer survival and follow-up, and in particular in cases of re-irradiation. 
Differential diagnosis with tumour progression is often difficult. Treatment of symptomatic patients 




may be used, as an option to decrease the surrounding oedema, usually at a dose of 7.5 mg/kg 
every 2 weeks for a median of 4 cycles. Prospective randomised trials are needed to further 
validate this option. 
LMD   
There is no accepted standard of care for breast cancer LMD. The choice of treatment (RT, intra-
CSF therapy, systemic therapy, supportive care) should consider prognostic evaluation and 
multidisciplinary discussion.  
Expert opinion 95% 
Focal RT should be considered for circumscribed, notably symptomatic lesions.  Expert opinion 95% 
WBRT can be considered for extensive nodular or symptomatic linear LMD.  Expert opinion 95% 
Addition of intrathecal to systemic therapy has no OS or QoL advantage and no clinically 
meaningful effect on CSF progression.  
II/D 95% 
Intrathecal therapy can be considered if systemic disease is stable and there is normal CSF flow, 
when there is evidence of malignant cells in the CSF (type I LMD). Significant toxicity may occur. 
Expert opinion 95% 
Liver metastases   
Prospective RCTs of local therapy for breast cancer liver metastases are urgently needed since 
available evidence comes only from series in highly selected patients. Since there are no 
randomised data supporting the effect of local therapy on survival, every patient must be informed 
of this when discussing a potential local therapy technique. Local therapy should only be proposed 
in very selected cases of good PS, with limited liver involvement and no extrahepatic lesions, after 






to select the best technique for the individual patient (surgery, stereotactic RT, intrahepatic ChT, 
etc.). 
Malignant pleural effusions   
Malignant pleural effusions require systemic treatment with/without local management. 
Thoracentesis for diagnosis should be performed if it is likely that this will change clinical 
management. False negative results are common. 
Drainage is recommended in patients with symptomatic, clinically significant pleural effusion. 
Use of an intrapleural catheter or intrapleural administration of talc or drugs (e.g. bleomycin, 
biological response modifiers) can be helpful. 







Chest wall and regional (nodal) recurrences   
Due to the high risk of concomitant distant metastases, patients with chest wall or regional (nodal) 




Chest wall and regional recurrences should be treated with surgical excision when feasible with 
limited risk of morbidity. 
II/A 97% 
Locoregional RT is indicated for patients not previously irradiated. II/A 97% 







In addition to local therapy (surgery and/or RT), in the absence of distant metastases, the use of 
systemic therapy (ChT, ET and/or anti-HER2 therapy) should be considered. 
I/B 95% 
ChT after first local or regional recurrence improves long-term outcomes in ER-negative disease 
and can be used. 
I/B 95% 
ET in this setting improves long-term outcomes for ER-positive disease and should be used. I/B 95% 
The choice of systemic treatment depends on tumour biology, previous treatments, length of DFI 




In patients with disease not amenable to radical local treatment, the choice of palliative systemic 
therapy should be made according to principles previously defined for metastatic disease. These 




In green, NEW ABC 5 statements. 
ABC, advanced breast cancer; ChT, chemotherapy; consensus, percentage of panel members in agreement with the 
statement; CPG, Clinical Practice Guideline; CSF, cerebrospinal fluid; DFI, disease-free interval; ER, oestrogen receptor; 
ESMO, European Society for Medical Oncology; ET, endocrine therapy; GoR, grade of recommendation; HER2, human 
epidermal growth factor receptor 2; LMD, leptomeningeal disease; LoE, level of evidence; MRI, magnetic resonance imaging; 





The ABC panel decided to endorse the ESMO Clinical Practice Guideline (CPG) related to 
the use of bone-targeted agents (bisphosphonate, denosumab), which replace all previous 
statements regarding this subject.100  
Leptomeningeal disease (LMD) is a rare complication of breast cancer with a 5% incidence 
rate. LMD carries a poor prognosis, with a median OS of approximately 4 weeks which can be 
prolonged to a few months in some patients with aggressive multimodal treatment.101 Its 
diagnosis is based on clinical evaluation, cerebrospinal magnetic resonance imaging (MRI) 
and cerebrospinal fluid (CSF) analysis. The European Association of Neuro-oncology (EANO) 
and ESMO have proposed to classify LMD using two major criteria: presence (type I) or not 
(type II) of positive CSF and neuroimaging findings.102 The same authors have proposed to 
define the therapeutic plan based on the presentation of the disease [nodular (A) or linear (B) 
or mixed (C) meningeal involvement, positive CSF cytology, presence or not of extracerebral 
disease, etc.] and taking into account the patient’s life expectancy.103 Available active 
treatment options are RT, intra-CSF therapy and systemic therapy. The choice of treatment 
should always involve multidisciplinary discussion. Currently, there is no accepted standard of 
care for breast cancer LMD and recommendations are essentially expert opinion based. The 
EANO-ESMO CPG recommend considering focal RT for circumscribed, notably symptomatic 
lesions, and whole-brain RT (WBRT) for extensive nodular or symptomatic linear LMD.102 The 
use of intrathecal therapy is controversial. It is recommended in cases where tumour cells are 
present in the CSF; it is optional in cases of linear metastatic meningeal disease.101-103 This 
strategy is not recommended in patients with obstructive hydrocephalus (RT can be used to 
restore CSF flow and successful restoration should be checked before the use of any 
intrathecal treatment) or in patients with nodular meningeal metastases only. Three agents 
are commonly used for intrathecal treatment of LMD: methotrexate, cytarabine (including 
liposomal cytarabine) or thioTEPA.101-103 Their use can cause a spectrum of toxicities ranging 
from myelosuppression to neurotoxicity. Methotrexate is the most commonly used agent. 
Neurotoxicity is increased with the use of methotrexate and RT and this combination is not 
recommended. Other agents, such as trastuzumab for HER2-positive disease, are under 
evaluation. Intrathecal therapy can be considered in cases where systemic disease is stable. 
However, two prospective trials have shown that the addition of intrathecal to systemic 
therapy has no OS or QoL advantage.103 Retrospective data suggest some activity of different 
agents used systemically.101-103 
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Section X: specific populations 
Guideline statement LoE/GoR Consensus 
Advanced male breast cancer   
For ER-positive male ABC, which represents the majority of cases, ET is the preferred option 
unless there is visceral crisis or rapidly progressive disease needing a fast response. 
III/A 100% 
For ER-positive male ABC, tamoxifen is the preferred option. IV/B 83% 
For male patients with ABC who need to receive an AI, a concomitant LHRH agonist or 
orchidectomy is the preferred option. AI monotherapy may also be considered with close monitoring 
of response. 
Clinical trials are needed in this patient population. 
IV/B 86% 
No new statements for this section were developed at ABC 5. 
ABC, advanced breast cancer; AI, aromatase inhibitor; consensus, percentage of panel members in agreement with the 
statement; ER, oestrogen receptor; ET, endocrine therapy; GoR, grade of recommendation; LHRH, luteinising hormone-




Section XI: LABCa 
Guideline statement LoE/GoR Consensus 
Before starting any therapy, a core biopsy providing histology and biomarker expression (ER, PgR, 
HER2, proliferation/grade) is indispensable to guide treatment decisions. 
I/A 97% 
Since LABC patients have a significant risk of metastatic disease, a full staging work-up, including a 
complete history, physical examination, laboratory tests and imaging of the chest and abdomen 
(preferably with a CT scan) and bone before initiation of systemic therapy is highly recommended. 
I/A 100% 
PET-CT, if available, may be used (instead of and not in addition to CT scans and a bone scan).  II/B 100% 
Systemic therapy (not surgery or RT) should be the initial treatment. 
If LABC remains inoperable after systemic therapy and eventual RT, ‘palliative’ mastectomy should 





A combined treatment modality based on a multidisciplinary approach (systemic therapy, surgery and 
RT) is strongly indicated in the vast majority of cases. 
I/A 100% 
Options for HR-positive LABC include an anthracycline- and taxane-based ChT regimen, or ET. 
The choice of ChT versus ET as initial treatment will depend on tumour (grade, biomarker 





For triple-negative LABC, anthracycline- and taxane-based ChT is recommended as initial 
treatment. 




For HER2-positive LABC, concurrent taxane and anti-HER2 therapy is recommended since it 
increases the rate of pCR.  
I/A 92% 
For HER2-positive LABC, anthracycline-based ChT should be incorporated into the treatment 
regimen. 
I/A 72% 
When an anthracycline is given, it should be administered sequentially with the anti-HER2 therapy. I/A 87% 
For patients with HER2-positive LABC (inflammatory or non-inflammatory), without distant 
metastases, who are in complete remission after appropriate preoperative systemic therapy and 
appropriate locoregional therapy, and being treated with a potential curative intent, the approved 
adjuvant duration of 1 year of anti-HER2 therapy should be used. 
I/A 85% 
Following effective preoperative systemic therapy with or without RT, surgery will be possible in many 
patients. This will consist of mastectomy with axillary dissection in the majority of cases, but in 
selected patients with a good response, BCS may be possible. 
II/A 98% 
In patients with axillary low burden of disease at presentation (previously cN0–cN1) with complete 
response after systemic treatment (ycN0), SLNB can be an option, provided all the recommendations 
for sentinel node after primary systemic treatment are followed (i.e. dual tracer, clipping/marking 
positive nodes, minimum of three sentinel nodes). 
III/B 62% 
Inflammatory LABC   
For inflammatory LABC, overall treatment recommendations are similar to those for non-inflammatory 




Mastectomy with axillary dissection is recommended in almost all cases, even when there is good 
response to primary systemic therapy. 
I/A 95% 
Immediate reconstruction is generally not recommended in patients with inflammatory LABC. IV/E 95% 
Locoregional RT (chest wall and lymph nodes) is required, even when a pCR is achieved with 
systemic therapy. 
I/A 98% 
No new statements for this section were developed at ABC 5. 
ABC, advanced breast cancer; BCS, breast-conserving surgery; ChT, chemotherapy; consensus, percentage of panel members 
in agreement with the statement; ChT, chemotherapy; CT, computed tomography; ER, oestrogen receptor; ET, endocrine 
therapy; GoR, grade of recommendation; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LABC, 
locally advanced breast cancer; LoE, level of evidence; pCR, pathological complete response; PET, positron emission 
tomography; PgR, progesterone receptor; PS, performance status; QoL, quality of life; RT, radiotherapy; SLNB, sentinel lymph 
node biopsy. 





Section XII: supportive and palliative care 
Guideline statement LoE/GoR Consensus 
Supportive care allowing safer and more tolerable delivery of appropriate treatments should 
always be part of the treatment plan. 
I/A 100% 
Early introduction of expert palliative care, including effective control of pain and other symptoms, 
should be a priority. 
I/A 100% 
Access to effective pain treatment (including morphine, which is inexpensive) is necessary for all 
patients in need of pain relief. 
I/A 100% 
The ABC community is aware of the limitations that are being imposed worldwide, as a 
consequence of the opioid use disorders in certain areas of the world. The ABC community is 
united in insisting that cancer patients should not have restrictions placed that will limit their access 




The panel encourages research on the potential role of cannabis to assist with pain and symptom 
control but strongly stresses that it cannot replace proven medicines such as morphine, for 
adequate pain control. 
I/C 97% 
Optimally, discussions about patient preferences at the end of life should begin early in the course 
of metastatic disease. However, when active treatment no longer is able to control widespread and 
life-threatening disease, and the toxicities of remaining options outweigh the benefits, physicians 
and other members of the healthcare team should initiate discussions with the patient (and family 






Management of cancer-related fatigue   
Cancer-related fatigue is frequently experienced by patients with ABC, exerts a deleterious impact 
on QoL and limits physical, functional, psychological and social well-being. The aetiology of this 
fatigue is complex; therefore, effective management needs to be multidimensional. 
It is important to assess cancer-related fatigue using appropriate PROMs before implementing 
various non-pharmacological (such as exercise [I, A]), and, if needed, pharmacological 







Management of CDK inhibitor-induced neutropaenia   
Neutropaenia is the most common toxicity associated with CDK4/6 inhibition and is not generally 
associated with febrile neutropaenia, although an increase in infections has been reported. 
Treatment should be delayed until neutrophils have recovered to at least 1000/μl; dose reduction 
can also be considered.  
II/A 100% 
Management of NIP    
NIP is an uncommon complication of mTOR inhibition or CDK4/6 inhibition. Patient education is 
critical to ensure early reporting of respiratory symptoms. Treatment interruption and dose 
reduction are generally effective for grade 2 symptomatic NIP with the use of systemic steroids 
and treatment discontinuation for grade 3 or greater toxicity. 
II/A 100% 
Management of dyspnoea   
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Treatable causes like pleural effusion, pulmonary emboli, cardiac insufficiency, anaemia or drug 
toxicity must be ruled out. Patient support is essential. Oxygen is of no use in non-hypoxic 
patients. 
Opioids are the drugs of choice in the palliation of dyspnoea. 
Benzodiazepines can be used in patients experiencing anxiety. 
Steroids can be effective in dyspnoea caused by lymphangitis carcinomatosis, RT or drug-induced 
pneumonitis, superior vena cava syndrome, an inflammatory component or in (cancer-induced) 









Management of nausea and vomiting   
ESMO/MASCC guidelines104 are available for the management of ChT-induced and morphine-
induced nausea and vomiting, and these are endorsed by the ABC community. 






Management of endocrine toxicities from mTOR or PIK3CA inhibition   
Hyperglycaemia and hyperlipidaemia are common, sub-acute complications of mTOR or PIK3CA 
inhibition. Evaluation of pre-existing diabetes or hyperglycaemia at baseline is essential. Regular, 
careful monitoring of glycemia and lipid panel is needed to identify these toxicities. 
Management of grade 1 and 2 hyperglycaemia includes treatment with oral antidiabetics and basal 
insulin, in accordance with international recommendations for diabetes mellitus treatment. Statins 
are indicated to treat grade 2 and 3 hypercholesterolaemia, and fibrates should be introduced if 




everolimus and fibrates). Treatment interruption and dose reduction are generally effective for 
grade 2 and 3 toxicity. Treatment should be discontinued for grade 4 toxicity. 
Management of mucositis/stomatitis   
Steroid mouthwash should be used for the prevention of stomatitis induced by mTOR inhibitors 
(suggested schedule: 0.5 mg/5 ml dexamethasone, 10 ml to swish x 2 minutes, then spit out; 
q.i.d.). 
Early intervention is recommended. 
For grade >2 stomatitis, delaying treatment until the toxicity resolves and considering lowering the 
dose of the targeted agent are also recommended. 
Mild toothpaste and gentle hygiene are recommended for the treatment of stomatitis. 














Management of CIPN   
CIPN is frequent and potentially dose-limiting. Risk factors for neuropathy and pre-existing 
neuropathy need to be identified. 
No medical prevention can currently be recommended. 








The use of tight gloves and socks during ChT may help reduce the incidence and severity of CIPN. 
There are limited evidence-based treatments for CIPN, with tricyclic antidepressants, serotonin-
noradrenaline reuptake inhibitors, duloxetine, pregabalin and gabapentin being most often used. 






Management of HFS   
HFS is also described as palmar-plantar erythrodysesthaesia syndrome. Most frequent causes are 
capecitabine, pegylated liposomal doxorubicin and multikinase inhibitors. 
Patients should be instructed about early recognition of HFS. 
Drug-related factors (dosing, timing, route) can lower the risk of HFS. 
Treatment of hyperkeratosis/fungal infections, comfortable shoes and avoidance of friction and 
heat are recommended. 
Intensive skin care of hands and feet (urea cream/ointment) is recommended. 










Management of postmenopausal symptoms   
Systemic hormone therapy is generally not recommended to treat postmenopausal symptoms in 
ABC patients, particularly not in ER-positive disease.  











• For postmenopausal symptoms in general: Mind-body interventions, physical training and 
CBT are effective non-pharmacological treatment options. 
• For hot flushes: Venlafaxine, oxybutynin, gabapentin, clonidine and acupuncture are 
available options. 
• For sleep disturbances: Melatonin 
There is no convincing evidence that phytotherapeutic drugs improve postmenopausal symptoms. 











Sexual health   
Sexuality is an experience on many levels and is not confined to the act of intercourse. Sexuality 
remains important for many ABC patients. ABC patients frequently experience impaired sexual 
health and need specific attention. Openly addressing misconceptions and sexual challenges after 
treatment, as well as educating patients, have been shown to improve QoL. When life expectancy 
is limited, physical contact, affection, emotional communication and comfort are particularly 




Dyspareunia   
Dyspareunia is often caused by vaginal dryness.  
The first choice for treating vaginal dryness and soreness are hormone-free lubricants and 
moisturisers (e.g. water-based gel, hyaluronic acid gel). 
If hormone-free measures are not effective, low-dose oestrogen-containing vaginal medication 












The value of local testosterone application and of invasive measures like vaginal laser or 
hyaluronic acid injections is still unclear. 
In green, NEW ABC 5 statements. 
ABC, advanced breast cancer; CBT, cognitive behavioural therapy; CDK, cyclin-dependent kinase; ChT, chemotherapy; CIPN, 
chemotherapy-induced peripheral neuropathy; consensus, percentage of panel members in agreement with the statement; ER, 
oestrogen receptor; ESMO, European Society for Medical Oncology; GoR, grade of recommendation; HFS, hand and foot 
syndrome; LoE, level of evidence; MASCC, Multinational Association of Supportive Care in Cancer; mTOR, mammalian target 
of rapamycin; n/a, not applicable; NIP, non-infectious pneumonitis; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase 





Since its onset, ABC meetings and guidelines have highlighted and fought for early and equal 
access to effective pain treatment (including morphine, which is inexpensive) for all patients in 
need of pain relief.105 Yet, in Europe and all over the world, there is inadequate and very 
unequal access to pain control,106 and the recent ESMO guidelines107 are difficult to follow in 
those countries where the majority of patients experiencing cancer pain live. Recent years 
have seen a drawback in adequate cancer pain management, even in wealthy countries, due 
to what is known as the opioid epidemic, which has a myriad of causes and will not be solved 
by any simple solution.108 Consequent to a staggering increase in opioid-related deaths in the 
United States, various governmental inputs and stakeholder strategies have been proposed 
and implemented with varying success. Recent trends in opioid-related data demonstrate an 
almost fourfold increase in overdose deaths from 1999 to 2008. Stricter prescribing practices 
and prescription monitoring programmes have been instituted but unfortunately these have 
raised obstacles for cancer patients. Several organisations, such as ASCO,109 have been 
calling for measures to ensure adequate protection of cancer patients. The ABC panel 
strongly supports this position and states that no restrictions should be in place that limit 
cancer patients’ access to adequate pain control. 
Recent data on cannabidiol for medical use has not yet substantiated claims indicating 
that it is effective in cancer pain management to the same level as morphine110 and more 
research is needed.111 
Many therapies for ABC are associated with oestrogen deprivation and patients often 
suffer from menopausal symptoms such as hot flushes, night sweats, sleep disturbances, 
fatigue, arthralgia, cognitive impairment, depression and vaginal dryness, as well as impaired 
sexual functioning (e.g. loss of sexual desire, dyspareunia). Hormone replacement therapy is 
contraindicated due to the endocrine character of the disease and should not be used to treat 
complaints. Nevertheless, the final decision belongs to the patient, after adequate information, 
since in some cases these symptoms are impacting significantly on QoL.112,113 For 
menopausal symptoms in general, mind-body interventions, physical training and cognitive 
behavioural therapy should be recommended as effective non-pharmacological treatment 
options.114-118 To control hot flushes, valid alternatives are venlafaxine, oxybutynin, 
gabapentin and clonidine.119-122 Sleep disturbances may be treated with melatonin.123,124 
There is no convincing evidence that phytotherapeutic drugs may improve menopausal 
symptoms. Possible drug interactions must be considered. 
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Sexuality is an experience on many levels and is not confined to the act of intercourse. 
ABC patients frequently experience impaired sexual health and need specific attention. A 
recent retrospective study showed that breast cancer patients are more affected than patients 
with ovarian cancer or healthy controls: decreased or no interest in sexual activity was 
frequently reported with a significant association to less satisfaction and more discomfort 
(dyspareunia); however, the lack of desire was not associated with global health status, QoL 
or the ability to experience orgasms; oestrogen deprivation (gonadotropin-releasing hormone 
agonists, AIs) seemed to have more impact than tamoxifen.125 
Dyspareunia is often caused by vaginal dryness. The first choice for treating vaginal dryness 
and soreness are hormone-free lubricants (e.g. water-based gel, hyaluronic acid gel). 126-128 If 
hormone-free measures are not effective, low-dose estriol-containing vaginal medication may 
be used.129-133 The value of local testosterone application and of invasive measures like 
vaginal laser or hyaluronic acid injections is still unclear.134-136 In summary, gynaecological 
and sexual symptoms are important challenges for most ABC patients. In particular, even in 
an anonymous setting, patients are often too shy to report their problems regarding impaired 
sexual life. Therefore, active verbalisation of gynaecological and sexual symptoms in an 
adequate and trustful atmosphere is a mandatory part of follow-up visits. Openly addressing 
misconceptions and sexual challenges after treatment, as well as educating patients, have 
been shown to improve QoL. When life expectancy is limited, physical contact, affection, 
emotional communication and comfort are particularly important. Standardised instruments 
(questionnaires) may help to assess the grade of impairment.137-141 At first recurrence, one 
out of four patients is younger than 50 years old and premenopausal. Therefore, issues of 
fertility and contraception must be discussed, and for the latter, only hormone-free 
contraceptives can be recommended.142 
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Section XIII: integrative medicinea 
Guideline statement LoE/GoR Consensus 
Alternative therapies (i.e. therapies used instead of scientifically-based medicines) are not 
recommended in any phase or stage of cancer treatment. 
n/a/E 100% 
Breast cancer centres/units/departments should be aware that the majority of their patients would 
like to be informed about CIM and that many of them are using it. Physicians should actively ask for 
information about its use in view of the potential deleterious interactions with specific anticancer 
therapies. If complementary therapies are not available at the centre, certified contacts should be 
available to promote referral to practitioners qualified in the therapies people are interested in 
receiving. 
Expert opinion/C 100% 
Some complementary therapies have the potential to reduce disease symptom burden and/or side 
effects of anticancer therapies, and therefore improve the QoL of ABC patients. 
Expert opinion/C 100% 
Evidence suggests beneficial effects of the following methods, which can therefore be used: 
• Physical exercise/sport (equivalent to 3–5 hours of moderate walking per week) improves 
QoL, cardiorespiratory fitness, physical performance and fatigue, and it may also improve 
DFS and OS. 
• MBSR programmes, hypnosis and yoga may improve QoL and fatigue, and help reduce 
anxiety, distress and some side effects of anticancer therapies. 




Methods with no or unfavourable effects 
The following methods of alternative medicine are not recommended in ABC since available 
evidence shows no effect at best, or even association with worse outcome: 
o Antioxidant supplements 
o Drugs outside the approved indication (e.g. methadone) 
o Herbs including Chinese herbal medicine 
o Orthomolecular substances (selenium, zinc...) 
o Oxygen and ozone therapy 
o Proteolytic enzymes, thymic peptides 
o Phytoestrogens (soy food, isoflavones) 
o High-dose vitamins (vitamin C, D, E, carotenoids, etc.) 
o L-carnitine, laetrile 
II/E 100% 
No new statements for this section were developed at ABC 5. 
ABC, advanced breast cancer; ChT, chemotherapy; CIM, complementary and integrative medicine; consensus, percentage of panel 
members in agreement with the statement; DFS, disease-free survival; GoR, grade of recommendation; LoE, level of evidence; 
MBSR, mindfulness-based stress reduction; n/a, not applicable; OS, overall survival; QoL, quality of life. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
ABC guidelines provide a useful tool for the management of ABC in clinical practice. Each 
guideline has an associated LoE, GoR and percentage of consensus. Additionally, version 1.1 
of the ESMO-MCBS13 was applied to drugs approved by the EMA after 2016. As usual, if 
additional new agents are approved by the EMA before the next ABC Consensus 
Conference, the ESMO-MCBS will be applied and the result will be made available as an 
eUpdate to the present guidelines. 
We acknowledge that in many areas of the world, some of these guidelines may not be 
implemented due to the existence of disparities in access. It is the mission of the ABC Global 
Alliance143 to fight for better outcomes for all ABC patients around the world. For this goal to 
be achieved, efforts must continue not only in research but also in public policy to ensure 
equal access to multidisciplinary, specialised care, including anticancer, palliative and end-of-
life care, and full implementation of these guidelines. We emphasise again that 
reimbursement rules in all countries should be patient-centred and be an incentive, not work 
against, the clinical implementation of high-quality international guidelines. Clinical trials and 
consequent approval and reimbursement must not continue to exclude certain groups of 
patients, such as premenopausal women and men, which keep seeing their treatment options 
reduced in many countries. 
At a time when the world is facing the COVID-19 pandemic, the ABC community must 
unite to maintain or increase the resources needed to face the ever-rising cancer ‘epidemic’, 
which is responsible for 18.1 million new cases and 9.6 million deaths annually worldwide, 
with half of million deaths annually due to ABC.12 
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Supplementary Table S1. ESMO-MCBS table for new therapies/indications in ABC 
 
Therapy Disease setting Trial Control Absolute 
survival gain 









Abemaciclib as initial 
































fulvestrant in women 
with HR-
positive/HER2-
































OS gain: 9.4 
months 
 










0332991) + letrozole 
versus letrozole for 





































treated with ET 





with fulvestrant in HR-
positive, HER2-






























































PFS gain: 10.8 
months 
 




PFS HR: 0.55 
(0.44–0.69) 
 






































PFS gain: 7.7 
months 
 





PFS HR: 0.59 
(0.48–0.73) 
 













First-line ribociclib + 
letrozole versus 































































































































Olaparib for MBC in 

















PFS gain: 2.8 
months 
 




PFS HR: 0.58 
(0.43–0.80) 
 













patients with ABC and 





























MBC who have 

































































PFS gain: 2.2 
months 
 






PFS HR: 0.54 
(0.42–0.71)g 
 








ABC, advanced breast cancer; AI, aromatase inhibitor; CI, confidence interval; ChT, chemotherapy; DoR, duration of response; EMA, 
European Medicines Agency; ER, oestrogen receptor; ESMO-MCBS, European Society for Medical Oncology-Magnitude of Clinical Benefit 
Scale; ET, endocrine therapy; FDA, Food and Drug Administration; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; HR, 
hormone receptor; MBC, metastatic breast cancer; NS, not significant; ORR, objective response rate; OS, overall survival; PD-L1, programmed 
death-ligand 1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PE, point estimate; PFS, progression-free 
survival; QoL, quality of life; T-DM1, trastuzumab emtansine; TNBC, triple-negative breast cancer. 
a  ESMO-MCBS version 1.1.27 The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines 
Committee. 
b Calculated estimate of gain based on PE HR 0.54. 
c Calculated estimate of gain based on PE HR 0.71. 
d Calculated estimate of gain based on PE HR 0.72.  
e Overall survival was an exploratory, unplanned post hoc analysis not eligible for ESMO-MCBS grading. 
f FDA-approved; EMA evaluation ongoing. 
g PFS on the first 480 patients randomised. 





Supplementary Table S2. Levels of evidence and grades of recommendation 
(adapted from the Infectious Disease Society of America-United State Public Health 
Service Grading Systema) 
Levels of evidence 
I Evidence from at least one large randomised, controlled trial of good 
methodological quality (low potential for bias) or meta-analyses of well-
conducted randomised trials without heterogeneity 
II Small randomised trials or large randomised trials with a suspicion of bias 
(lower methodological quality) or meta-analyses of such trials or of trials with 
demonstrated heterogeneity 
III Prospective cohort studies 
IV Retrospective cohort studies or case–control studies  
 
V Studies without control group, case reports, expert opinions 
 
Grades of recommendation 
A Strong evidence for efficacy with a substantial clinical benefit, strongly 
recommended 
B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally 
recommended 
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the 
disadvantages (adverse events, costs, etc.), optional  
D Moderate evidence against efficacy or for adverse outcome, generally not 
recommended 
E Strong evidence against efficacy or for adverse outcome, never recommended 
 
a Reprinted by permission of Oxford University Press on behalf of the Infectious Diseases 
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Diagnosis and treatment Survivorship issues
Breast imaging [I, A]
Suspicion of  
locoregional progression
End-of-life care
Discussed with patients  
early in course of  
metastatic disease 
[expert opinion, A]
Access to personalised supportive 
and psychological care and 
symptom-related intervention 
from time of diagnosis, allowing 
for safer/more tolerable delivery  
of treatment, taking into account 
patient preferences, values and 
needs [expert opinion, A]
Breast reconstruction in cases 
where disease is in complete 
remission or stable and patient  
preference [expert opinion, B]
SUPPLEMENTARY FIGURES: ADVANCED BREAST CANCER (ABC 5) ALGORITHMS
Figure S1. ABC follow-up and supportive carea
Open communication  
between patients and  
care team  
[expert opinion, A]
Educating patients  
on treatment and  
supportive care  
[expert opinion, A]
Systematic monitoring of patients to 
permit early intervention of supportive 
care to enhance QoL [I, C]
Encouraging patients  
to be proactive in  
their care and share  
decision-making with  
cancer care teams 
[expert opinion, A]
Empowering patients to 
improve their own QoL 
[expert opinion, A]
ABC, advanced breast cancer; QoL, quality of life.
a Throughout the cancer pathway, adequate information should be provided to the patient.
Supportive care
LABC ABC
Figure S2. ABC diagnostic work-up and staging
ABC, advanced breast cancer; CT, computed tomography; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; LABC, locally advanced breast cancer;  
MRI, magnetic resonance imaging; PET, positron emission tomography; PgR, progesterone receptor.










Core biopsy to evaluate 
histology and biomarker 
expression (ER, PgR, HER2, 
proliferation/grade) [I, A]
Biopsy of metastatic lesion 
to confirm ABC diagnosis, 
particularly if first incidence of 
metastatic disease [I, B]
Staging work-up: history and physical examination, haematology,  
biochemistry, tumour markers and imaging of chest, abdomen and bone with CT,  
bone scan [II, A] or PET-CTa [II, B]
Reassess biomarkers  
(ER, PgR and HER2) at least once 
in the metastatic setting [I, B]
LABC
Initial therapy should be 
systemic [III, A]
Initial therapy depends on tumour 
and patient characteristics
Triple-negative LABCHR+ HER2- LABC
ET or ChT 
[I, A] ChT [I, A]
Further systemic  
treatment 




Continue anti-HER2 therapy for at least 1 
year [I, A] if HER2+
Start/continue ET for at least 5 years [I, A]
Operable tumour
Non-inflammatory Inflammatory
Mastectomy with AD [I, A]Mastectomy with AD [II, A] 
or BCS if appropriate [II, A]
RT (if not given previously) [I, A]
ABC, advanced breast cancer; AD, axillary dissection; BCS, breast-conserving surgery;  ChT, chemotherapy; ET, endocrine therapy; HER2, human epidermal growth factor 
receptor 2; HR, hormone receptor; LABC, locally advanced breast cancer; RT, radiotherapy.
a LABC per ABC 5 definition, i.e. inoperable, locally advanced without distant metastases.
Figure S3. Treatment of LABCa
Combined treatment strongly 
indicated in most cases [I, A]
HER2+ LABC
 Tumour remains  
inoperable
Non-inflammatory ChT + anti-HER2 therapy [I, A]ChT [I, A]Inflammatory
or
Diagnosis of ER+/HER2- ABCFigure S4. Treatment of ER-positive/HER2-negative ABC
a




AI + CDK4/6 inhibitor (if >12 
months since AI) [I, A] or 
fulvestrant + CDK4/6 inhibitor [I, A]
If CDK4/6 inhibitor not available or in selected 
cases where not needed (see text for details)
Tamoxifen [I, A]PARPi if gBRCA mut Fulvestrant [I, A] AI [I, A]
ChT (patients with visceral 
crisis or without further ET 
options)
Sequential single-agent 
ChT (preferred) [I, A]
Combination ChT (selected 
patients with rapid 
progression, visceral crisis, 
need for rapid symptom/
disease control) [I, A]
Previously
untreated








or taxane [I, A]
Capecitabine 
[I, A] Eribulin [I, A]
Vinorelbine 
[I, A]
ChT: capecitabine, eribulin, vinorelbine, anthracycline (if not used previously), 
taxane (if not used previously) [I, A]

















ABC, advanced breast cancer; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; ChT, chemotherapy; DFI, disease-free interval; ER, oestrogen receptor; ESMO-MCBS, ESMO Magnitude of Clinical Benefit Scale; HER2, human epidermal growth factor 
receptor 2; PARPi, poly-adenosine diphosphate ribose polymerase inhibitor; PIK3CA, phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha.
a For ESMO-MCBS scores, please refer to the manuscript and https://www.esmo.org/Guidelines/ESMO-MCBS.
b Rechallenge with a taxane or anthracycline is possible if cumulative dose not reached and DFI ≥12 months.
Different ET + CDK4/6 inhibitor if not previously used [I, A], different 
ET + everolimus [I, B], different AI [I, A], fulvestrant [I, A], tamoxifen  
[I, A], oestradiol [I, A], megestrol acetate [I, A]
Fulvestrant + 
alpelisib [I, B]
If alpelisib not available
Previously untreated
with anti-HER2 therapy
Patients unsuitable for ChT or 




Other option not previously used 





Previously treated with (neo)
adjuvant pertuzumab + 
trastuzumab with a DFI 
<6–12 months
ChT + trastuzumab + 
pertuzumab [I, A] 
(ChT + trastuzumab if  
pertuzumab not available [I, A])
Anti-HER2 (trastuzumab ± 
pertuzumab or lapatinib)  
+ ET [I, B]
ChT + trastuzumab 
or ChT + pertuzumab
+ trastuzumab [I, A]
Diagnosis of HER2+ ABC
Optimal duration of maintenance 
anti-HER2 therapy is unknown
Stopping therapy after  
several years of remission 
may be an option
Anti-HER2 as maintenance 
therapy [I, A]
+ ET if ER+ [n/a, B] 
Tucatinib + 
trastuzumab + 
capecitabine [II, B] 







Trastuzumab + an 
unused ChT agent 
[II, A]
Trastuzumab + an 
unused ET agent 
if ER+ [II, A]
Figure S5. Treatment of HER2-positive ABCa,b
ABC, advanced breast cancer; ChT, chemotherapy; CNS, central nervous system; DFI, disease-free interval; ER, oestrogen receptor; ESMO-MCBS, ESMO Magnitude of Clinical Benefit Scale; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; 
PARPi, poly-adenosine diphosphate ribose polymerase inhibitor; T-DM1,  trastuzumab-emtansine.
a Include in clinical trials when available.








Fourth line  
and beyond
T-DM1 if available [I, A]
Diagnosis of
triple-negative ABC
1. Complete testing for germline 
BRCA mutation [I, A] 
























single-agent ChT [I, A]
Combination ChT
(selected patients with rapid 
progression, visceral crisis,  
need for rapid symptom/ 
disease control) [I, A]
Carboplatin [I, A] Anthracyclineor taxanes [I, A]
Anti-PD-L1 + taxane [I, B]
ABC, advanced breast cancer; ChT, chemotherapy; ESMO-MCBS, ESMO Magnitude of Clinical Benefit Scale; PARPi, poly-adenosine diphosphate ribose polymerase inhibitor;  
PD-L1, programmed death-ligand 1.
a Include in clinical trials when available.
b For ESMO-MCBS scores, please refer to the manuscript and https://www.esmo.org/Guidelines/ESMO-MCBS.
c Refer to relevant guidelines for PD-L1 testing.
d If PARPi unavailable, preference should be given to a platinum agent [I, A].
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Continue at current dose to 
complete cycle 
Repeat complete blood  
count on day 21
Consider dose reduction
in cases of prolonged (>1  
week) recovery from grade 
3 neutropaenia or recurrent 
grade 3 neutropaenia in  








to mTOR or CDK4/6 
inhibitors
Patient education 




dose reduction [II, A]
Grade ≥3







Steroid mouthwash for 
prevention [I, B]
Mild toothpaste and 
dental hygiene [expert 
opinion, B] 
Grade ≥2
Lower dose of  targeted 
agent/delay treatment 
[expert opinion, A]
Patient support essential  
as well as treatment of  












ABC, advanced breast cancer; CDK, cyclin-dependent kinase; ESMO, European Society for Medical Oncology; MASCC, Multinational Association of Supportive Care in Cancer; mTOR, mammalian target of rapamycin;  PROM, patient-reported outcome measure.
Figure S7. ABC symptom control
Access to pain 
relief including 













Oral antidiabetics and 
basal insulin [II, A]
Treatment  
discontinuation [II, A]
Statins, fibrates, treatment 
interruption, dose reduction [II, A]
Treatment  discontinuation [II, A]
Tight gloves and socks 






duloxetine, pregabalin and 
gabapentin often used but 
evidence is limited [II, B]




Baseline evaluation of  
pre-existing diabetes/  
hyperglycaemia
Regular monitoring




Grade 2/3  
hypercholesterolaemia
Grade 4  
hypercholesterolaemia
ABC, advanced breast cancer; CBT, cognitive behavioural therapy; CIPN, chemotherapy-induced peripheral neuropathy; HFS, hand and foot syndrome; mTOR, mammalian target of rapamycin;  PROM, patient-reported outcome measure.
Figure S7 (continued). ABC symptom control
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(dosing, timing, route) 
can lower risk
Drug-related factors 
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Intensive skin care of 
hands and feet (urea 
cream/ointment) [II, A] Hot flushes: venlafaxine, 
oxybutynin, gabapentin, 
clonidine, acupuncture [I, B]
